≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Testicular dysfunction, other/unspecified

DOID EFO Endpoint Browser PheWeb

E4_TESTICDYSNAS

testicular disease: A non-neoplastic or neoplastic disorder affecting the testis. Representative examples include torsion, infarction, germ cell tumor, sex cord-stromal tumor, lymphoma, and leukemia.

Suggest a new description

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

only males

226725

2. Check conditions

None

226725

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — E29.8, E29.9
  • Hospital discharge: ICD-9 — 257[8-9]
  • Hospital discharge: ICD-8 — 2579
  • Cause of death: ICD-10 — E29.8, E29.9
  • Cause of death: ICD-9 — 257[8-9]
  • Cause of death: ICD-8 — 2579

2 out of 7 registries used, show all original rules.

206

4. Check minimum number of events

None

206

5. Include endpoints

None

206

6. Filter based on genotype QC (FinnGen only)

199

Control definitions (FinnGen only)

Control exclude
E4_ENDOGLAND

Extra metadata

Level in the ICD hierarchy
4
First used in FinnGen datafreeze
DF2

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 1111 - 1111
Only index persons 1058 - 1058
Unadjusted period prevalence (%)
Whole population 0.03 - 0.03
Only index persons 0.04 - 0.04
Median age at first event (years)
Whole population - - 39.11
Only index persons - - 39.11

-FinnGen-

Key figures

All Female Male
Number of individuals 199 - 199
Unadjusted period prevalence (%) 0.09 - 0.09
Median age at first event (years) 51.48 - 51.48

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
206
Matched controls
2060
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G03BA03
ATC
testosterone; systemic, rectal, sublingual, transdermal
54.9
191.9
135
69
E29.9
ICD-10 Finland
Testicular dysfunction, unspecified
2114.5
169.3
141
*
E29.1
ICD-10 Finland
Testicular hypofunction
38.5
77.5
50
17
E29.8
ICD-10 Finland
Other testicular dysfunction
+∞
73.4
66
*
E23.04
ICD-10 Finland
Hypogonadotropic hypogonadism
38.6
67.2
43
14
A55
ICPC
General and Unspecified, Local injection/infiltration
45.9
23.3
28
7
101
Kela drug reimbursment
Anterior pituitary hypofunction
+∞
20.1
19
*
A50
ICPC
General and Unspecified, Medication/prescr/renewal
9.2
20.1
26
32
121
Kela drug reimbursment
Severe hypofunction of sexual glands
184.3
16.8
17
*
KF8AE
NOMESCO Finland
Ultrasound examination of scrotum
6.3
16.1
29
52
WVA30, ,
SPAT
5.8
14.6
29
57
AA4CG
NOMESCO Finland
Extensive MRI examination of sella turcica with high intensity magnet
+∞
11.6
11
*
G47.3
ICD-10 Finland
Sleep apnoea
2.8
11.1
86
425
Y28
ICPC
Limited function/disability (Y)
45.9
11.1
13
*
Z03.80
ICD-10 Finland
Observation for other suspected diseases and conditions
9.3
9.0
18
21
N02AX02
ATC
tramadol; systemic, rectal
2.3
8.0
104
630
R53
ICD-10 Finland
Malaise and fatigue
2.5
7.5
57
272
R10.3
ICD-10 Finland
Pain localized to other parts of lower abdomen
2.7
6.8
41
174
N03AX16
ATC
[U] pregabalin
2.4
6.6
51
244
G03GA01
ATC
chorionic gonadotrophin; parenteral
72.0
6.5
7
*
N45.9
ICD-10 Finland
Orchitis, epididymitis and epididymo-orchitis without abscess
4.1
6.4
18
47
-50
ICPC
Medication/prescr/renewal
7.4
6.3
14
20
Z71.2
ICD-10 Finland
Person consulting for explanation of investigation findings
2.3
6.1
60
318

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
testosterone; oral, parenteral, rectal, sublingual, transdermal
G03BA03 [21602510]
3.5e+00
4.4e+00
4.5e+00
—
5.1e+00
4.9e+00
4.7e+00
cases:34.16%
controls:1.53%
cases:42.57%
controls:0.94%
cases:18.81%
controls:0.25%
—
—
cases:28.14%
controls:0.25%
cases:54.29%
controls:0.88%
cases:55.30%
controls:1.14%
69
31
133
1989
86
19
116
2001
38
5
164
2015
—
56
5
143
2003
95
16
80
1806
73
15
59
1298
Testosterone [Moles/volume] in Serum or Plasma
14913-8 [3017446]
2.1e+00
2.8e+00
4.8e+00
—
3.2e+00
2.7e+00
2.4e+00
cases:32.18%
controls:5.64%
cases:31.19%
controls:2.67%
cases:23.76%
controls:0.25%
—
—
cases:9.05%
controls:0.40%
cases:31.43%
controls:2.85%
cases:45.45%
controls:7.01%
65
114
137
1906
63
54
139
1966
48
5
154
2015
—
18
8
181
2000
55
52
120
1770
60
92
72
1221
androstanolone
A14AA01 [21600917]
3.6e+00
4.4e+00
—
—
—
4.8e+00
4.7e+00
cases:27.23%
controls:1.04%
cases:33.66%
controls:0.59%
—
—
—
—
—
—
cases:43.43%
controls:0.60%
cases:48.48%
controls:0.84%
55
21
147
1999
68
12
134
2008
—
—
—
76
11
99
1811
64
11
68
1302
androstanolone
G03BB02 [21602513]
3.5e+00
4.3e+00
—
—
—
4.6e+00
4.6e+00
cases:23.76%
controls:0.89%
cases:28.22%
controls:0.54%
—
—
—
—
—
—
cases:34.86%
controls:0.55%
cases:42.42%
controls:0.76%
48
18
154
2002
57
11
145
2009
—
—
—
61
10
114
1812
56
10
76
1303
Sex hormone binding globulin [Moles/volume] in Serum or Plasma
13967-5 [3004248]
2.4e+00
3.3e+00
—
—
3.6e+00
3.3e+00
2.6e+00
cases:22.28%
controls:2.48%
cases:17.82%
controls:0.79%
—
—
—
—
cases:8.04%
controls:0.25%
cases:21.14%
controls:0.93%
cases:29.55%
controls:2.89%
45
50
157
1970
36
16
166
2004
—
—
16
5
183
2003
37
17
138
1805
39
38
93
1275
Testosterone Free [Moles/volume] in Serum or Plasma by calculation
96559-0 [36032269]
2.3e+00
3.5e+00
—
—
—
2.9e+00
2.7e+00
cases:17.82%
controls:2.13%
cases:14.36%
controls:0.50%
—
—
—
—
—
—
cases:12.00%
controls:0.77%
cases:26.52%
controls:2.28%
36
43
166
1977
29
10
173
2010
—
—
—
21
14
154
1808
35
30
97
1283
Endocrinology
46 [38004485]
1.4e+00
1.8e+00
—
1.0e+50
2.8e+00
3.0e+00
1.8e+00
cases:10.40%
controls:2.67%
cases:7.43%
controls:1.34%
—
—
cases:13.86%
controls:0.00%
cases:4.52%
controls:0.30%
cases:22.86%
controls:1.43%
cases:20.45%
controls:4.11%
21
54
181
1966
15
27
187
1993
—
28
0
174
2020
9
6
190
2002
40
26
135
1796
27
54
105
1259
tadalafil; oral
G04BE08 [21602653]
1.7e+00
1.8e+00
—
1.0e+50
2.5e+00
2.3e+00
1.8e+00
cases:13.86%
controls:2.97%
cases:9.41%
controls:1.63%
—
—
cases:2.48%
controls:0.00%
cases:6.53%
controls:0.60%
cases:14.29%
controls:1.70%
cases:21.21%
controls:4.34%
28
60
174
1960
19
33
183
1987
—
5
0
197
2020
13
12
186
1996
25
31
150
1791
28
57
104
1256
Lutropin [Units/volume] in Serum or Plasma
10501-5 [3009214]
2.6e+00
—
1.0e+50
—
—
3.6e+00
2.2e+00
cases:8.42%
controls:0.64%
—
—
cases:6.93%
controls:0.00%
—
—
—
—
cases:9.14%
controls:0.27%
cases:7.58%
controls:0.91%
17
13
185
2007
—
14
0
188
2020
—
—
16
5
159
1817
10
12
122
1301
Prostate Specific Ag Free/Prostate specific Ag.total in Serum or Plasma
12841-3 [3001784]
8.6e-01
9.7e-01
2.8e+00
—
1.6e+00
8.3e-01
1.2e+00
cases:36.14%
controls:19.26%
cases:20.79%
controls:9.06%
cases:9.41%
controls:0.64%
—
—
cases:4.52%
controls:0.95%
cases:17.71%
controls:8.56%
cases:43.18%
controls:18.74%
73
389
129
1631
42
183
160
1837
19
13
183
2007
—
9
19
190
1989
31
156
144
1666
57
246
75
1067
Urology
34 [38004474]
1.0e+00
1.3e+00
1.1e+00
1.0e+50
2.4e+00
2.0e+00
1.2e+00
cases:23.76%
controls:10.25%
cases:16.83%
controls:5.30%
cases:3.47%
controls:1.24%
cases:42.08%
controls:0.00%
cases:10.55%
controls:1.10%
cases:29.14%
controls:5.05%
cases:31.06%
controls:11.58%
48
207
154
1813
34
107
168
1913
7
25
195
1995
85
0
117
2020
21
22
178
1986
51
92
124
1730
41
152
91
1161
Outpatient Visit
OP [9202]
4.4e-01
6.0e-01
4.5e-01
4.1e+00
7.4e-01
7.0e-01
9.3e-01
cases:84.65%
controls:78.07%
cases:67.33%
controls:53.12%
cases:14.85%
controls:10.00%
cases:21.78%
controls:0.45%
cases:19.10%
controls:10.16%
cases:68.00%
controls:51.37%
cases:87.12%
controls:72.81%
171
1577
31
443
136
1073
66
947
30
202
172
1818
44
9
158
2011
38
204
161
1804
119
936
56
886
115
956
17
357
Prostate specific Ag [Mass/volume] in Serum or Plasma
2857-1 [3013603]
7.0e-01
8.7e-01
2.3e+00
—
1.3e+00
6.9e-01
1.2e+00
cases:40.10%
controls:24.95%
cases:26.73%
controls:13.32%
cases:11.88%
controls:1.34%
—
—
cases:5.53%
controls:1.54%
cases:22.86%
controls:12.95%
cases:54.55%
controls:26.50%
81
504
121
1516
54
269
148
1751
24
27
178
1993
—
11
31
188
1977
40
236
135
1586
72
348
60
965
Case Management Agency
251B00000X [38004193]
2.9e-01
4.6e-01
8.5e-01
4.6e+00
8.6e-01
7.5e-01
4.3e-01
cases:84.16%
controls:79.95%
cases:81.68%
controls:73.81%
cases:52.97%
controls:32.43%
cases:67.82%
controls:2.08%
cases:53.77%
controls:32.97%
cases:86.29%
controls:74.75%
cases:91.67%
controls:87.74%
170
1615
32
405
165
1491
37
529
107
655
95
1365
137
42
65
1978
107
662
92
1346
151
1362
24
460
121
1152
11
161
Cortisol [Moles/volume] in Serum or Plasma
14675-3 [3036481]
1.4e+00
2.0e+00
—
—
—
1.8e+00
1.6e+00
cases:5.45%
controls:1.39%
cases:3.47%
controls:0.50%
—
—
—
—
—
—
cases:4.00%
controls:0.66%
cases:8.33%
controls:1.75%
11
28
191
1992
7
10
195
2010
—
—
—
7
12
168
1810
11
23
121
1290
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
9.3e-01
1.1e+00
—
—
2.0e+00
1.5e+00
9.7e-01
cases:18.81%
controls:8.37%
cases:8.91%
controls:3.17%
—
—
—
—
cases:3.02%
controls:0.40%
cases:9.14%
controls:2.20%
cases:15.91%
controls:6.70%
38
169
164
1851
18
64
184
1956
—
—
6
8
193
2000
16
40
159
1782
21
88
111
1225
Pharmacy visit
OMOP4822462 [581458]
2.6e-01
9.0e-01
1.1e+00
1.9e+00
1.3e+00
9.4e-01
2.0e+00
cases:95.54%
controls:94.31%
cases:92.08%
controls:82.52%
cases:69.31%
controls:42.82%
cases:14.36%
controls:2.43%
cases:73.37%
controls:44.07%
cases:92.00%
controls:81.78%
cases:99.24%
controls:94.52%
193
1905
9
115
186
1667
16
353
140
865
62
1155
29
49
173
1971
146
885
53
1123
161
1490
14
332
131
1241
1
72
CBC panel - Blood by Automated count
58410-2 [40761511]
1.9e-01
6.4e-01
1.4e+00
2.2e+00
7.8e-01
6.4e-01
7.6e-01
cases:55.94%
controls:51.19%
cases:41.58%
controls:27.28%
cases:17.33%
controls:4.75%
cases:3.47%
controls:0.40%
cases:10.05%
controls:4.88%
cases:40.00%
controls:26.07%
cases:67.42%
controls:49.20%
113
1034
89
986
84
551
118
1469
35
96
167
1924
7
8
195
2012
20
98
179
1910
70
475
105
1347
89
646
43
667
Prostate Specific Ag Free [Mass/volume] in Serum or Plasma
10886-0 [3005013]
1.0e+00
1.0e+00
—
—
2.2e+00
7.2e-01
1.1e+00
cases:27.72%
controls:12.28%
cases:15.35%
controls:6.04%
—
—
—
—
cases:4.52%
controls:0.50%
cases:10.86%
controls:5.60%
cases:32.58%
controls:14.01%
56
248
146
1772
31
122
171
1898
—
—
9
10
190
1998
19
102
156
1720
43
184
89
1129
Laboratory Visit
OMOP4822461 [32036]
9.5e-02
5.7e-01
1.2e+00
2.8e+00
7.2e-01
4.0e-01
3.9e-01
cases:69.80%
controls:67.77%
cases:68.81%
controls:55.50%
cases:40.59%
controls:16.88%
cases:11.39%
controls:0.74%
cases:29.65%
controls:16.98%
cases:65.14%
controls:55.60%
cases:80.30%
controls:73.50%
141
1369
61
651
139
1121
63
899
82
341
120
1679
23
15
179
2005
59
341
140
1667
114
1013
61
809
106
965
26
348
sildenafil; oral
G04BE03 [21602648]
1.3e+00
1.2e+00
7.1e-01
—
5.9e-01
1.4e+00
1.2e+00
cases:31.19%
controls:11.24%
cases:20.79%
controls:7.52%
cases:3.47%
controls:1.73%
—
—
cases:3.02%
controls:1.69%
cases:24.57%
controls:7.46%
cases:31.06%
controls:11.73%
63
227
139
1793
42
152
160
1868
7
35
195
1985
—
6
34
193
1974
43
136
132
1686
41
154
91
1159
Prolactin [Units/volume] in Serum or Plasma
15081-3 [3021387]
2.5e+00
—
—
—
—
—
2.2e+00
cases:5.94%
controls:0.50%
—
—
—
—
—
—
—
—
—
—
cases:4.55%
controls:0.53%
12
10
190
2010
—
—
—
—
—
6
7
126
1306
Supplier / Service Provider
OMOP5117446 [33004]
-5.1e-01
1.4e-01
—
—
—
1.9e+00
2.8e+00
cases:22.28%
controls:32.23%
cases:7.43%
controls:6.53%
—
—
—
—
—
—
cases:4.57%
controls:0.71%
cases:15.91%
controls:1.14%
45
651
157
1369
15
132
187
1888
—
—
—
8
13
167
1809
21
15
111
1298
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
1.4e-01
4.4e-01
8.8e-01
3.0e+00
7.4e-01
3.7e-01
6.8e-01
cases:53.96%
controls:50.54%
cases:42.57%
controls:32.33%
cases:11.88%
controls:5.30%
cases:6.44%
controls:0.35%
cases:11.56%
controls:5.88%
cases:38.86%
controls:30.57%
cases:68.94%
controls:53.01%
109
1021
93
999
86
653
116
1367
24
107
178
1913
13
7
189
2013
23
118
176
1890
68
557
107
1265
91
696
41
617
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
9.3e-02
5.4e-01
1.1e+00
2.8e+00
6.2e-01
3.0e-01
5.6e-01
cases:63.86%
controls:61.68%
cases:56.44%
controls:43.02%
cases:24.26%
controls:9.36%
cases:7.92%
controls:0.50%
cases:17.59%
controls:10.31%
cases:50.86%
controls:43.36%
cases:77.27%
controls:66.11%
129
1246
73
774
114
869
88
1151
49
189
153
1831
16
10
186
2010
35
207
164
1801
89
790
86
1032
102
868
30
445
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
1.3e-01
4.4e-01
8.7e-01
3.0e+00
7.1e-01
3.7e-01
6.6e-01
cases:53.96%
controls:50.69%
cases:43.07%
controls:32.82%
cases:11.88%
controls:5.35%
cases:6.44%
controls:0.35%
cases:11.56%
controls:6.03%
cases:39.43%
controls:31.01%
cases:68.94%
controls:53.47%
109
1024
93
996
87
663
115
1357
24
108
178
1912
13
7
189
2013
23
121
176
1887
69
565
106
1257
91
702
41
611
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
9.1e-02
5.2e-01
1.2e+00
2.8e+00
6.0e-01
3.2e-01
5.5e-01
cases:63.86%
controls:61.73%
cases:56.44%
controls:43.56%
cases:24.75%
controls:9.36%
cases:7.92%
controls:0.54%
cases:17.59%
controls:10.46%
cases:51.43%
controls:43.52%
cases:77.27%
controls:66.18%
129
1247
73
773
114
880
88
1140
50
189
152
1831
16
11
186
2009
35
210
164
1798
90
793
85
1029
102
869
30
444
Platelets [#/volume] in Blood
26515-7 [3007461]
8.4e-02
5.4e-01
1.1e+00
2.8e+00
6.1e-01
3.0e-01
5.6e-01
cases:63.37%
controls:61.39%
cases:56.44%
controls:43.07%
cases:24.26%
controls:9.31%
cases:7.92%
controls:0.54%
cases:17.59%
controls:10.41%
cases:50.86%
controls:43.36%
cases:77.27%
controls:65.96%
128
1240
74
780
114
870
88
1150
49
188
153
1832
16
11
186
2009
35
209
164
1799
89
790
86
1032
102
866
30
447
MCH [Entitic mass]
28539-5 [3035941]
9.5e-02
5.3e-01
1.1e+00
2.8e+00
6.1e-01
3.0e-01
5.6e-01
cases:63.86%
controls:61.63%
cases:56.44%
controls:43.22%
cases:24.26%
controls:9.36%
cases:7.92%
controls:0.54%
cases:17.59%
controls:10.36%
cases:50.86%
controls:43.41%
cases:77.27%
controls:66.03%
129
1245
73
775
114
873
88
1147
49
189
153
1831
16
11
186
2009
35
208
164
1800
89
791
86
1031
102
867
30
446
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
9.3e-02
5.3e-01
1.1e+00
2.8e+00
6.1e-01
3.0e-01
5.5e-01
cases:63.86%
controls:61.68%
cases:56.44%
controls:43.27%
cases:24.26%
controls:9.36%
cases:7.92%
controls:0.54%
cases:17.59%
controls:10.41%
cases:50.86%
controls:43.36%
cases:77.27%
controls:66.18%
129
1246
73
774
114
874
88
1146
49
189
153
1831
16
11
186
2009
35
209
164
1799
89
790
86
1032
102
869
30
444
Leukocytes [#/volume] in Blood
26464-8 [3010813]
8.7e-02
5.3e-01
1.1e+00
2.8e+00
6.1e-01
3.0e-01
5.5e-01
cases:63.86%
controls:61.83%
cases:56.44%
controls:43.27%
cases:24.26%
controls:9.36%
cases:7.92%
controls:0.54%
cases:17.59%
controls:10.41%
cases:50.86%
controls:43.47%
cases:77.27%
controls:66.18%
129
1249
73
771
114
874
88
1146
49
189
153
1831
16
11
186
2009
35
209
164
1799
89
792
86
1030
102
869
30
444
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
9.3e-02
5.3e-01
1.1e+00
2.8e+00
6.1e-01
3.0e-01
5.6e-01
cases:63.86%
controls:61.68%
cases:56.44%
controls:43.27%
cases:24.26%
controls:9.36%
cases:7.92%
controls:0.54%
cases:17.59%
controls:10.41%
cases:50.86%
controls:43.41%
cases:77.27%
controls:66.11%
129
1246
73
774
114
874
88
1146
49
189
153
1831
16
11
186
2009
35
209
164
1799
89
791
86
1031
102
868
30
445
Thyroxine (T4) free [Moles/volume] in Serum or Plasma
14920-3 [3008486]
5.3e-01
9.0e-01
2.2e+00
—
—
3.0e-01
7.2e-01
cases:36.63%
controls:25.45%
cases:23.27%
controls:10.99%
cases:8.42%
controls:1.04%
—
—
—
—
cases:13.14%
controls:10.10%
cases:40.91%
controls:25.13%
74
514
128
1506
47
222
155
1798
17
21
185
1999
—
—
23
184
152
1638
54
330
78
983
Hyperplasia of prostate
N40 [45563015]
8.4e-01
8.6e-01
—
1.0e+50
2.3e+00
1.1e+00
6.3e-01
cases:11.88%
controls:5.50%
cases:6.93%
controls:3.07%
—
—
cases:5.45%
controls:0.00%
cases:3.52%
controls:0.35%
cases:8.57%
controls:2.96%
cases:13.64%
controls:7.77%
24
111
178
1909
14
62
188
1958
—
11
0
191
2020
7
7
192
2001
15
54
160
1768
18
102
114
1211
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
1.2e-01
2.1e-01
8.9e-01
3.2e+00
4.2e-01
1.1e-01
5.3e-01
cases:43.07%
controls:40.25%
cases:32.67%
controls:28.32%
cases:12.38%
controls:5.50%
cases:6.93%
controls:0.30%
cases:10.55%
controls:7.17%
cases:29.14%
controls:26.84%
cases:58.33%
controls:45.16%
87
813
115
1207
66
572
136
1448
25
111
177
1909
14
6
188
2014
21
144
178
1864
51
489
124
1333
77
593
55
720
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
9.9e-03
3.6e-01
9.6e-01
3.0e+00
6.0e-01
7.1e-02
3.3e-01
cases:48.02%
controls:47.77%
cases:37.62%
controls:29.60%
cases:14.36%
controls:6.04%
cases:6.44%
controls:0.35%
cases:12.06%
controls:7.02%
cases:30.86%
controls:29.36%
cases:54.55%
controls:46.23%
97
965
105
1055
76
598
126
1422
29
122
173
1898
13
7
189
2013
24
141
175
1867
54
535
121
1287
72
607
60
706
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
4.7e-02
4.6e-01
9.6e-01
2.9e+00
5.5e-01
2.9e-01
4.9e-01
cases:57.92%
controls:56.78%
cases:50.99%
controls:39.65%
cases:16.83%
controls:7.18%
cases:6.93%
controls:0.40%
cases:13.57%
controls:8.27%
cases:45.71%
controls:38.58%
cases:71.97%
controls:61.23%
117
1147
85
873
103
801
99
1219
34
145
168
1875
14
8
188
2012
27
166
172
1842
80
703
95
1119
95
804
37
509
Thyrotropin [Units/volume] in Serum or Plasma
3016-3 [3009201]
4.5e-01
8.7e-01
2.1e+00
—
1.1e+00
4.8e-02
6.4e-01
cases:46.53%
controls:35.79%
cases:33.66%
controls:17.57%
cases:13.37%
controls:1.88%
—
—
cases:5.53%
controls:1.89%
cases:17.14%
controls:16.47%
cases:52.27%
controls:36.63%
94
723
108
1297
68
355
134
1665
27
38
175
1982
—
11
38
188
1970
30
300
145
1522
69
481
63
832
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
1.8e-01
5.9e-01
4.7e-01
3.0e+00
1.2e-01
3.4e-01
4.8e-01
cases:50.99%
controls:46.49%
cases:39.11%
controls:26.34%
cases:6.93%
controls:4.46%
cases:7.43%
controls:0.40%
cases:6.03%
controls:5.38%
cases:32.00%
controls:25.08%
cases:59.85%
controls:47.91%
103
939
99
1081
79
532
123
1488
14
90
188
1930
15
8
187
2012
12
108
187
1900
56
457
119
1365
79
629
53
684
Prostate specific Ag panel - Serum or Plasma
53764-7 [3039443]
1.9e+00
1.7e+00
—
—
—
—
1.7e+00
cases:8.42%
controls:1.39%
cases:3.96%
controls:0.74%
—
—
—
—
—
—
—
—
cases:5.30%
controls:0.99%
17
28
185
1992
8
15
194
2005
—
—
—
—
7
13
125
1300
Sleep apnoea
G47.3 [45562094]
8.8e-01
8.3e-01
1.0e+00
—
9.8e-01
1.2e+00
1.4e+00
cases:17.82%
controls:8.27%
cases:10.40%
controls:4.80%
cases:2.48%
controls:0.89%
—
—
cases:3.52%
controls:1.34%
cases:15.43%
controls:5.16%
cases:29.55%
controls:9.44%
36
167
166
1853
21
97
181
1923
5
18
197
2002
—
7
27
192
1981
27
94
148
1728
39
124
93
1189
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
R5110 [2001310246]
1.8e-01
—
—
—
—
2.1e+00
1.4e+00
cases:3.47%
controls:2.92%
—
—
—
—
—
—
—
—
cases:3.43%
controls:0.44%
cases:10.61%
controls:2.89%
7
59
195
1961
—
—
—
—
6
8
169
1814
14
38
118
1275
25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma
68438-1 [40771025]
5.4e-01
6.6e-01
2.4e+00
—
—
5.3e-01
9.3e-01
cases:15.84%
controls:9.90%
cases:11.39%
controls:6.24%
cases:6.93%
controls:0.69%
—
—
—
—
cases:9.71%
controls:5.98%
cases:30.30%
controls:14.70%
32
200
170
1820
23
126
179
1894
14
14
188
2006
—
—
17
109
158
1713
40
193
92
1120
Orthopedic Surgery
20 [38004465]
7.3e-01
8.4e-01
1.3e+00
—
9.9e-01
9.8e-01
7.2e-01
cases:27.72%
controls:15.64%
cases:12.87%
controls:5.99%
cases:3.47%
controls:0.99%
—
—
cases:2.51%
controls:0.95%
cases:15.43%
controls:6.42%
cases:25.76%
controls:14.39%
56
316
146
1704
26
121
176
1899
7
20
195
2000
—
5
19
194
1989
27
117
148
1705
34
189
98
1124
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
-8.3e-02
3.7e-01
7.5e-01
3.1e+00
4.0e-01
2.1e-01
5.3e-01
cases:41.09%
controls:43.12%
cases:38.12%
controls:29.95%
cases:11.39%
controls:5.74%
cases:5.45%
controls:0.25%
cases:9.55%
controls:6.62%
cases:33.14%
controls:28.65%
cases:61.36%
controls:48.21%
83
871
119
1149
77
605
125
1415
23
116
179
1904
11
5
191
2015
19
133
180
1875
58
522
117
1300
81
633
51
680
Holo-transcobalamin II [Moles/volume] in Serum
72160-5 [43054903]
-1.8e-01
9.2e-01
2.1e+00
—
1.5e+00
4.3e-01
6.8e-01
cases:9.41%
controls:11.04%
cases:11.88%
controls:5.10%
cases:4.46%
controls:0.59%
—
—
cases:3.02%
controls:0.70%
cases:6.29%
controls:4.17%
cases:25.00%
controls:14.47%
19
223
183
1797
24
103
178
1917
9
12
193
2008
—
6
14
193
1994
11
76
164
1746
33
190
99
1123
Triglyceride [Moles/volume] in Serum or Plasma --fasting
47210-0 [3048773]
1.8e-01
4.4e-01
1.5e+00
—
1.2e+00
8.8e-02
3.8e-01
cases:50.00%
controls:45.59%
cases:28.22%
controls:20.25%
cases:9.90%
controls:2.38%
—
—
cases:8.04%
controls:2.49%
cases:22.86%
controls:21.35%
cases:52.27%
controls:42.73%
101
921
101
1099
57
409
145
1611
20
48
182
1972
—
16
50
183
1958
40
389
135
1433
69
561
63
752
Cholesterol in LDL [Moles/volume] in Serum or Plasma
22748-8 [3001308]
1.8e-01
4.1e-01
1.5e+00
—
1.2e+00
1.2e-01
3.8e-01
cases:54.46%
controls:49.85%
cases:36.63%
controls:27.82%
cases:11.88%
controls:2.97%
—
—
cases:10.55%
controls:3.34%
cases:31.43%
controls:28.87%
cases:64.39%
controls:55.29%
110
1007
92
1013
74
562
128
1458
24
60
178
1960
—
21
67
178
1941
55
526
120
1296
85
726
47
587
Cholesterol in HDL [Moles/volume] in Serum or Plasma
14646-4 [3023602]
1.9e-01
4.8e-01
1.5e+00
—
1.2e+00
6.3e-02
3.3e-01
cases:52.97%
controls:48.12%
cases:34.65%
controls:24.70%
cases:11.88%
controls:2.82%
—
—
cases:9.05%
controls:2.99%
cases:26.86%
controls:25.63%
cases:60.61%
controls:52.55%
107
972
95
1048
70
499
132
1521
24
57
178
1963
—
18
60
181
1948
47
467
128
1355
80
690
52
623
Cholesterol [Moles/volume] in Serum or Plasma
14647-2 [3019900]
1.4e-01
4.1e-01
1.5e+00
—
1.2e+00
2.1e-02
3.0e-01
cases:51.98%
controls:48.51%
cases:34.16%
controls:25.54%
cases:11.88%
controls:2.87%
—
—
cases:9.05%
controls:2.99%
cases:26.86%
controls:26.45%
cases:59.85%
controls:52.55%
105
980
97
1040
69
516
133
1504
24
58
178
1962
—
18
60
181
1948
47
482
128
1340
79
690
53
623
flecainide; oral, parenteral
C01BC04 [21600266]
2.7e+00
—
—
—
—
—
—
cases:3.47%
controls:0.25%
—
—
—
—
—
—
—
—
—
—
—
—
7
5
195
2015
—
—
—
—
—
—
Outpatient Hospital
22 [8756]
6.6e-01
1.0e+00
—
—
—
9.6e-01
9.1e-01
cases:26.24%
controls:15.54%
cases:7.43%
controls:2.77%
—
—
—
—
—
—
cases:6.86%
controls:2.74%
cases:16.67%
controls:7.46%
53
314
149
1706
15
56
187
1964
—
—
—
12
50
163
1772
22
98
110
1215
alfuzosin; oral
G04CA01 [21602668]
8.2e-01
1.4e+00
—
—
—
1.3e+00
1.2e+00
cases:7.43%
controls:3.42%
cases:5.45%
controls:1.39%
—
—
—
—
—
—
cases:5.71%
controls:1.65%
cases:11.36%
controls:3.88%
15
69
187
1951
11
28
191
1992
—
—
—
10
30
165
1792
15
51
117
1262
Intravenous general anesthesia
WX404 [2001310807]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.55%
controls:0.38%
—
—
—
—
—
—
6
5
126
1308
Scheduled procedure
ZXD10 [2001311387]
1.1e-01
—
—
—
—
2.4e+00
9.3e-01
cases:4.46%
controls:4.01%
—
—
—
—
—
—
—
—
cases:4.57%
controls:0.44%
cases:3.79%
controls:1.52%
9
81
193
1939
—
—
—
—
8
8
167
1814
5
20
127
1293
nebivolol; oral
C07AB12 [21601694]
2.3e+00
—
-1.0e+50
—
—
—
—
cases:2.97%
controls:0.30%
—
—
cases:0.00%
controls:0.25%
—
—
—
—
—
—
—
—
6
6
196
2014
—
0
5
202
2015
—
—
—
—
Fasting glucose [Moles/volume] in Serum or Plasma
14771-0 [3018251]
1.5e-01
5.0e-01
1.1e+00
—
1.2e+00
2.2e-01
2.7e-01
cases:48.02%
controls:44.41%
cases:29.70%
controls:20.40%
cases:6.93%
controls:2.33%
—
—
cases:7.54%
controls:2.49%
cases:24.00%
controls:20.20%
cases:50.00%
controls:43.34%
97
897
105
1123
60
412
142
1608
14
47
188
1973
—
15
50
184
1958
42
368
133
1454
66
569
66
744
Mixed anxiety and depressive disorder
F41.2 [45566845]
5.9e-01
2.2e+00
—
—
—
—
1.1e+00
cases:2.48%
controls:1.39%
cases:3.96%
controls:0.45%
—
—
—
—
—
—
—
—
cases:3.79%
controls:1.29%
5
28
197
1992
8
9
194
2011
—
—
—
—
5
17
127
1296
Cholesterol in LDL/Cholesterol in HDL [Mass Ratio] in Serum or Plasma
11054-4 [3002109]
9.0e-01
1.3e+00
—
—
—
6.4e-01
8.6e-01
cases:9.90%
controls:4.26%
cases:7.43%
controls:2.13%
—
—
—
—
—
—
cases:4.57%
controls:2.47%
cases:14.39%
controls:6.63%
20
86
182
1934
15
43
187
1977
—
—
—
8
45
167
1777
19
87
113
1226
Intraoperative use of conventional X-ray imaging
ZXM10 [2001311446]
—
—
—
—
—
-1.0e+50
2.2e+00
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
cases:4.55%
controls:0.53%
—
—
—
—
—
0
5
175
1817
6
7
126
1306
Hemoglobin A1c/Hemoglobin.total in Blood
4548-4 [3004410]
1.4e-01
5.6e-01
1.6e+00
—
6.6e-01
6.0e-02
5.5e-01
cases:44.55%
controls:41.14%
cases:36.14%
controls:24.41%
cases:10.40%
controls:2.33%
—
—
cases:6.53%
controls:3.49%
cases:26.29%
controls:25.14%
cases:62.12%
controls:48.67%
90
831
112
1189
73
493
129
1527
21
47
181
1973
—
13
70
186
1938
46
458
129
1364
82
639
50
674
Lipid panel - Serum or Plasma
100898-6 [1761868]
4.9e-01
6.0e-01
2.1e+00
—
1.6e+00
6.5e-02
4.4e-01
cases:24.75%
controls:16.83%
cases:14.85%
controls:8.71%
cases:5.94%
controls:0.74%
—
—
cases:3.52%
controls:0.70%
cases:9.14%
controls:8.62%
cases:30.30%
controls:21.93%
50
340
152
1680
30
176
172
1844
12
15
190
2005
—
7
14
192
1994
16
157
159
1665
40
288
92
1025
Blepharitis
H01.0 [45533180]
—
—
-1.0e+50
—
—
2.2e+00
2.1e+00
—
—
—
—
cases:0.00%
controls:0.25%
—
—
—
—
cases:2.86%
controls:0.33%
cases:5.30%
controls:0.69%
—
—
0
5
202
2015
—
—
5
6
170
1816
7
9
125
1304
Obesity due to excess calories
E66.01 [2000501501]
8.5e-01
—
—
—
—
2.1e+00
7.1e-01
cases:2.97%
controls:1.29%
—
—
—
—
—
—
—
—
cases:3.43%
controls:0.44%
cases:4.55%
controls:2.28%
6
26
196
1994
—
—
—
—
6
8
169
1814
6
30
126
1283
bupropion; oral
N06AX12 [21604741]
1.2e+00
2.1e+00
—
—
—
1.4e+00
8.4e-01
cases:3.96%
controls:1.19%
cases:4.95%
controls:0.64%
—
—
—
—
—
—
cases:2.86%
controls:0.71%
cases:3.79%
controls:1.68%
8
24
194
1996
10
13
192
2007
—
—
—
5
13
170
1809
5
22
127
1291
Prick test
37968009 [4242723]
2.1e+00
—
—
—
—
—
—
cases:3.47%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
7
9
195
2011
—
—
—
—
—
—
Sedation and analgesia
WX002 [2001310758]
1.5e-01
-1.0e+50
—
—
—
—
2.0e+00
cases:2.97%
controls:2.57%
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
cases:4.55%
controls:0.61%
6
52
196
1968
0
12
202
2008
—
—
—
—
6
8
126
1305
Bacteria identified in Stool by Culture
625-4 [3025941]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.55%
controls:0.61%
—
—
—
—
—
—
6
8
126
1305
Cystatin C [Mass/volume] in Serum or Plasma
33863-2 [3030366]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.33%
controls:1.22%
—
—
—
—
—
—
11
16
121
1297
Ultrasound measurement of residual urine
KC1EE [2001305918]
6.1e-01
—
—
—
—
2.0e+00
8.3e-01
cases:6.44%
controls:3.61%
—
—
—
—
—
—
—
—
cases:5.71%
controls:0.82%
cases:6.06%
controls:2.74%
13
73
189
1947
—
—
—
—
10
15
165
1807
8
36
124
1277
Mouth breathing
R06.5 [45573006]
1.4e+00
1.9e+00
—
—
—
—
2.0e+00
cases:3.96%
controls:0.99%
cases:2.48%
controls:0.40%
—
—
—
—
—
—
—
—
cases:5.30%
controls:0.76%
8
20
194
2000
5
8
197
2012
—
—
—
—
7
10
125
1303
mirtazapine; oral
N06AX11 [21604740]
7.2e-01
9.3e-01
1.3e+00
—
—
6.3e-01
1.0e+00
cases:12.87%
controls:6.68%
cases:8.91%
controls:3.71%
cases:2.97%
controls:0.79%
—
—
—
—
cases:6.29%
controls:3.46%
cases:17.42%
controls:6.93%
26
135
176
1885
18
75
184
1945
6
16
196
2004
—
—
11
63
164
1759
23
91
109
1222
Testosterone Free [Moles/volume] in Serum or Plasma
14914-6 [3018301]
1.7e+00
—
1.0e+50
—
—
—
1.9e+00
cases:3.47%
controls:0.64%
—
—
cases:2.97%
controls:0.00%
—
—
—
—
—
—
cases:6.06%
controls:0.91%
7
13
195
2007
—
6
0
196
2020
—
—
—
8
12
124
1301
Pulmonary Disease
29 [38004472]
8.4e-01
3.4e-01
—
—
—
8.0e-01
1.1e+00
cases:24.26%
controls:12.13%
cases:8.91%
controls:6.53%
—
—
—
—
—
—
cases:12.00%
controls:5.76%
cases:29.55%
controls:12.26%
49
245
153
1775
18
132
184
1888
—
—
—
21
105
154
1717
39
161
93
1152
combinations of corticosteroids
D07XB30 [21602188]
7.5e-01
1.1e+00
—
—
—
7.3e-01
2.7e-01
cases:20.79%
controls:11.04%
cases:10.40%
controls:3.61%
—
—
—
—
—
—
cases:8.00%
controls:4.01%
cases:12.88%
controls:10.13%
42
223
160
1797
21
73
181
1947
—
—
—
14
73
161
1749
17
133
115
1180
combinations of corticosteroids
D07AB30 [21602118]
7.5e-01
1.1e+00
—
—
—
7.3e-01
2.7e-01
cases:20.79%
controls:11.04%
cases:10.40%
controls:3.61%
—
—
—
—
—
—
cases:8.00%
controls:4.01%
cases:12.88%
controls:10.13%
42
223
160
1797
21
73
181
1947
—
—
—
14
73
161
1749
17
133
115
1180
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
4.6e-01
7.6e-01
1.9e+00
1.0e+50
—
2.9e-01
2.2e-01
cases:15.84%
controls:10.64%
cases:8.42%
controls:4.11%
cases:3.47%
controls:0.54%
cases:3.47%
controls:0.00%
—
—
cases:5.14%
controls:3.90%
cases:12.12%
controls:9.98%
32
215
170
1805
17
83
185
1937
7
11
195
2009
7
0
195
2020
—
9
71
166
1751
16
131
116
1182
One hour or less
ZXE00 [2001311394]
3.3e-01
—
—
—
—
1.8e+00
1.1e+00
cases:5.94%
controls:4.36%
—
—
—
—
—
—
—
—
cases:4.00%
controls:0.66%
cases:4.55%
controls:1.60%
12
88
190
1932
—
—
—
—
7
12
168
1810
6
21
126
1292
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
5.5e-01
6.3e-01
1.8e+00
—
9.4e-01
6.0e-01
6.7e-02
cases:26.73%
controls:17.38%
cases:11.88%
controls:6.68%
cases:4.95%
controls:0.84%
—
—
cases:2.51%
controls:1.00%
cases:11.43%
controls:6.59%
cases:18.18%
controls:17.21%
54
351
148
1669
24
135
178
1885
10
17
192
2003
—
5
20
194
1988
20
120
155
1702
24
226
108
1087
Inpatient Hospital
21 [8717]
4.8e-01
9.6e-01
—
—
1.2e+00
6.6e-01
8.5e-01
cases:27.23%
controls:18.76%
cases:10.89%
controls:4.46%
—
—
—
—
cases:2.51%
controls:0.80%
cases:8.00%
controls:4.28%
cases:19.70%
controls:9.52%
55
379
147
1641
22
90
180
1930
—
—
5
16
194
1992
14
78
161
1744
26
125
106
1188
vortioxetine; oral
N06AX26 [44819158]
8.5e-01
1.8e+00
—
—
—
—
1.1e+00
cases:2.97%
controls:1.29%
cases:3.47%
controls:0.59%
—
—
—
—
—
—
—
—
cases:4.55%
controls:1.60%
6
26
196
1994
7
12
195
2008
—
—
—
—
6
21
126
1292
Otolaryngology
4 [38004449]
8.0e-01
3.5e-01
—
—
—
1.9e-01
9.8e-01
cases:19.80%
controls:9.95%
cases:5.45%
controls:3.91%
—
—
—
—
—
—
cases:5.14%
controls:4.28%
cases:21.97%
controls:9.60%
40
201
162
1819
11
79
191
1941
—
—
—
9
78
166
1744
29
126
103
1187
Pain localized to other parts of lower abdomen
R10.3 [45534426]
8.0e-01
8.3e-01
—
—
—
1.7e+00
9.0e-01
cases:4.95%
controls:2.28%
cases:2.48%
controls:1.09%
—
—
—
—
—
—
cases:4.57%
controls:0.88%
cases:6.82%
controls:2.89%
10
46
192
1974
5
22
197
1998
—
—
—
8
16
167
1806
9
38
123
1275
Uroflowmetry
44856007 [4261340]
3.8e-01
—
—
—
—
1.6e+00
8.2e-01
cases:5.94%
controls:4.16%
—
—
—
—
—
—
—
—
cases:5.71%
controls:1.15%
cases:6.82%
controls:3.12%
12
84
190
1936
—
—
—
—
10
21
165
1801
9
41
123
1272
dapagliflozin; oral
A10BK01 [1123890]
8.0e-01
9.4e-01
—
—
—
1.6e+00
1.2e+00
cases:3.47%
controls:1.58%
cases:3.96%
controls:1.58%
—
—
—
—
—
—
cases:6.29%
controls:1.32%
cases:9.09%
controls:2.97%
7
32
195
1988
8
32
194
1988
—
—
—
11
24
164
1798
12
39
120
1274
codeine and paracetamol
N02AJ06 [1123647]
7.6e-01
8.5e-01
—
—
—
4.9e-03
5.8e-01
cases:32.18%
controls:18.12%
cases:12.38%
controls:5.69%
—
—
—
—
—
—
cases:6.29%
controls:6.26%
cases:23.48%
controls:14.62%
65
366
137
1654
25
115
177
1905
—
—
—
11
114
164
1708
31
192
101
1121
Drugs identified in Urine by Screen method Nominal
12286-1 [3011288]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.58%
controls:1.68%
—
—
—
—
—
—
10
22
122
1291
chondroitin sulfate
M01AX25 [21604013]
1.5e+00
—
—
—
—
—
—
cases:5.94%
controls:1.34%
—
—
—
—
—
—
—
—
—
—
—
—
12
27
190
1993
—
—
—
—
—
—
Feeling anxious/nervous/tense
P01 [2002000798]
7.7e-01
9.8e-01
—
—
—
1.1e+00
1.5e+00
cases:3.47%
controls:1.63%
cases:2.48%
controls:0.94%
—
—
—
—
—
—
cases:2.86%
controls:0.99%
cases:8.33%
controls:1.98%
7
33
195
1987
5
19
197
2001
—
—
—
5
18
170
1804
11
26
121
1287
Cholesterol non HDL [Moles/volume] in Serum or Plasma
70204-3 [42868678]
1.2e+00
1.5e+00
—
—
—
6.4e-01
7.8e-01
cases:5.94%
controls:1.88%
cases:5.45%
controls:1.29%
—
—
—
—
—
—
cases:4.00%
controls:2.14%
cases:12.12%
controls:5.94%
12
38
190
1982
11
26
191
1994
—
—
—
7
39
168
1783
16
78
116
1235
imidazoles/triazoles in combination with corticosteroids
D01AC20 [21601936]
8.6e-01
1.5e+00
—
—
—
6.7e-01
7.4e-01
cases:7.92%
controls:3.51%
cases:4.95%
controls:1.19%
—
—
—
—
—
—
cases:2.86%
controls:1.48%
cases:6.06%
controls:2.97%
16
71
186
1949
10
24
192
1996
—
—
—
5
27
170
1795
8
39
124
1274
fluticasone, combinations
R01AD58 [43534837]
7.3e-01
3.0e-01
-1.0e+50
—
—
1.4e+00
6.5e-01
cases:9.41%
controls:4.75%
cases:3.96%
controls:2.97%
cases:0.00%
controls:0.59%
—
—
—
—
cases:6.86%
controls:1.76%
cases:9.09%
controls:4.95%
19
96
183
1924
8
60
194
1960
0
12
202
2008
—
—
12
32
163
1790
12
65
120
1248
azelastine; nasal
R01AC03 [21605035]
7.3e-01
3.0e-01
-1.0e+50
—
—
1.4e+00
6.5e-01
cases:9.41%
controls:4.75%
cases:3.96%
controls:2.97%
cases:0.00%
controls:0.59%
—
—
—
—
cases:6.86%
controls:1.76%
cases:9.09%
controls:4.95%
19
96
183
1924
8
60
194
1960
0
12
202
2008
—
—
12
32
163
1790
12
65
120
1248
semaglutide; oral, parenteral
A10BJ06 [1501778]
1.4e+00
1.1e+00
1.2e+00
—
1.1e+00
—
7.7e-01
cases:5.45%
controls:1.39%
cases:4.95%
controls:1.68%
cases:2.97%
controls:0.94%
—
—
cases:3.02%
controls:1.00%
—
—
cases:8.33%
controls:4.04%
11
28
191
1992
10
34
192
1986
6
19
196
2001
—
6
20
193
1988
—
11
53
121
1260
antibiotics in combination with other drugs
S01AA20 [21603571]
4.5e-01
7.9e-01
—
—
—
1.4e+00
2.4e-01
cases:9.90%
controls:6.53%
cases:4.46%
controls:2.08%
—
—
—
—
—
—
cases:7.43%
controls:1.98%
cases:8.33%
controls:6.70%
20
132
182
1888
9
42
193
1978
—
—
—
13
36
162
1786
11
88
121
1225
oxycodone; oral, parenteral
N02AA05 [21604260]
1.4e+00
1.7e+00
—
—
—
—
8.3e-01
cases:5.45%
controls:1.44%
cases:2.48%
controls:0.45%
—
—
—
—
—
—
—
—
cases:6.06%
controls:2.74%
11
29
191
1991
5
9
197
2011
—
—
—
—
8
36
124
1277
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
2.0e-01
5.0e-01
8.5e-01
—
5.7e-01
1.1e-01
5.3e-01
cases:58.91%
controls:54.06%
cases:47.52%
controls:35.35%
cases:12.87%
controls:5.94%
—
—
cases:10.55%
controls:6.27%
cases:38.29%
controls:35.78%
cases:71.21%
controls:59.33%
119
1092
83
928
96
714
106
1306
26
120
176
1900
—
21
126
178
1882
67
652
108
1170
94
779
38
534
buprenorphine; parenteral, sublingual, transdermal
N02AE01 [21604287]
1.3e+00
1.0e+00
—
—
-1.0e+50
—
1.1e+00
cases:5.45%
controls:1.49%
cases:2.48%
controls:0.89%
—
—
—
—
cases:0.00%
controls:0.40%
—
—
cases:5.30%
controls:1.83%
11
30
191
1990
5
18
197
2002
—
—
0
8
199
2000
—
7
24
125
1289
diazepam; oral, parenteral, rectal
N05BA01 [21604566]
1.3e+00
1.2e+00
-1.0e+50
—
—
—
7.1e-01
cases:5.94%
controls:1.68%
cases:3.47%
controls:1.09%
cases:0.00%
controls:0.35%
—
—
—
—
—
—
cases:4.55%
controls:2.28%
12
34
190
1986
7
22
195
1998
0
7
202
2013
—
—
—
6
30
126
1283
cefalexin; oral
J01DB01 [21602870]
5.2e-01
7.3e-01
1.0e+00
—
—
5.1e-01
6.4e-01
cases:37.62%
controls:26.49%
cases:14.85%
controls:7.77%
cases:2.48%
controls:0.89%
—
—
—
—
cases:13.14%
controls:8.34%
cases:35.61%
controls:22.54%
76
535
126
1485
30
157
172
1863
5
18
197
2002
—
—
23
152
152
1670
47
296
85
1017
esomeprazole; oral, parenteral
A02BC05 [21600100]
6.6e-01
7.3e-01
1.3e+00
—
—
6.6e-01
1.2e+00
cases:11.88%
controls:6.49%
cases:8.42%
controls:4.26%
cases:2.97%
controls:0.79%
—
—
—
—
cases:6.86%
controls:3.68%
cases:17.42%
controls:5.94%
24
131
178
1889
17
86
185
1934
6
16
196
2004
—
—
12
67
163
1755
23
78
109
1235
meloxicam; oral, parenteral, rectal
M01AC06 [21603965]
1.2e+00
—
—
—
—
—
—
cases:7.43%
controls:2.38%
—
—
—
—
—
—
—
—
—
—
—
—
15
48
187
1972
—
—
—
—
—
—
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
5.2e-01
4.0e-01
5.7e-01
—
-5.4e-03
1.6e-01
6.4e-01
cases:41.58%
controls:29.70%
cases:23.27%
controls:16.83%
cases:5.45%
controls:3.17%
—
—
cases:3.52%
controls:3.54%
cases:17.71%
controls:15.48%
cases:44.70%
controls:29.86%
84
600
118
1420
47
340
155
1680
11
64
191
1956
—
7
71
192
1937
31
282
144
1540
59
392
73
921
Neurosurgery
14 [38004459]
1.2e+00
1.2e+00
—
—
—
1.3e+00
7.7e-01
cases:8.91%
controls:2.97%
cases:3.47%
controls:1.09%
—
—
—
—
—
—
cases:4.00%
controls:1.15%
cases:6.82%
controls:3.27%
18
60
184
1960
7
22
195
1998
—
—
—
7
21
168
1801
9
43
123
1270
Asthma, unspecified
J45.9 [45562456]
1.2e+00
8.3e-01
—
—
—
1.2e+00
4.9e-01
cases:7.92%
controls:2.62%
cases:2.48%
controls:1.09%
—
—
—
—
—
—
cases:4.00%
controls:1.26%
cases:6.06%
controls:3.81%
16
53
186
1967
5
22
197
1998
—
—
—
7
23
168
1799
8
50
124
1263
General Surgery
2 [38004447]
3.8e-01
1.2e+00
—
1.0e+50
—
4.3e-01
4.7e-01
cases:13.86%
controls:9.90%
cases:7.92%
controls:2.62%
—
—
cases:5.45%
controls:0.00%
—
—
cases:4.00%
controls:2.63%
cases:12.12%
controls:7.92%
28
200
174
1820
16
53
186
1967
—
11
0
191
2020
—
7
48
168
1774
16
104
116
1209
Hand Surgery
40 [38004480]
6.2e-01
—
—
—
—
—
1.1e+00
cases:6.44%
controls:3.56%
—
—
—
—
—
—
—
—
—
—
cases:10.61%
controls:3.88%
13
72
189
1948
—
—
—
—
—
14
51
118
1262
oxazepam; oral
N05BA04 [21604569]
1.1e+00
8.5e-01
—
—
—
8.5e-01
7.1e-01
cases:9.90%
controls:3.61%
cases:4.95%
controls:2.18%
—
—
—
—
—
—
cases:4.00%
controls:1.76%
cases:8.33%
controls:4.27%
20
73
182
1947
10
44
192
1976
—
—
—
7
32
168
1790
11
56
121
1257
Other and unspecified abdominal pain
R10.4 [45568113]
1.1e+00
7.8e-01
—
—
—
—
8.7e-01
cases:11.39%
controls:4.21%
cases:2.97%
controls:1.39%
—
—
—
—
—
—
—
—
cases:11.36%
controls:5.10%
23
85
179
1935
6
28
196
1992
—
—
—
—
15
67
117
1246
pregabalin; oral
N02BF02 [955152]
1.1e+00
7.9e-01
—
—
—
6.9e-01
6.9e-01
cases:11.39%
controls:4.26%
cases:4.46%
controls:2.08%
—
—
—
—
—
—
cases:3.43%
controls:1.76%
cases:6.06%
controls:3.12%
23
86
179
1934
9
42
193
1978
—
—
—
6
32
169
1790
8
41
124
1272
Person consulting for explanation of investigation findings
Z71.2 [45552100]
8.5e-01
4.3e-01
—
—
—
1.0e+00
1.1e+00
cases:8.42%
controls:3.76%
cases:3.96%
controls:2.62%
—
—
—
—
—
—
cases:4.00%
controls:1.48%
cases:15.91%
controls:6.17%
17
76
185
1944
8
53
194
1967
—
—
—
7
27
168
1795
21
81
111
1232
Ferritin [Mass/volume] in Serum or Plasma
2276-4 [3001122]
5.6e-01
1.0e+00
1.3e+00
—
1.1e+00
3.4e-01
5.6e-01
cases:16.34%
controls:10.05%
cases:16.34%
controls:6.44%
cases:3.96%
controls:1.14%
—
—
cases:2.51%
controls:0.85%
cases:8.00%
controls:5.82%
cases:22.73%
controls:14.39%
33
203
169
1817
33
130
169
1890
8
23
194
1997
—
5
17
194
1991
14
106
161
1716
30
189
102
1124
Upper gastrointestinal surgery
106 [44777669]
4.0e-01
9.8e-01
—
—
1.4e+00
7.7e-01
7.3e-01
cases:14.85%
controls:10.50%
cases:9.41%
controls:3.76%
—
—
—
—
cases:2.51%
controls:0.65%
cases:7.43%
controls:3.57%
cases:17.42%
controls:9.22%
30
212
172
1808
19
76
183
1944
—
—
5
13
194
1995
13
65
162
1757
23
121
109
1192
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
9.5e-01
6.3e-02
—
—
—
7.0e-01
3.7e-01
cases:14.85%
controls:6.34%
cases:2.48%
controls:2.33%
—
—
—
—
—
—
cases:5.71%
controls:2.91%
cases:9.85%
controls:7.01%
30
128
172
1892
5
47
197
1973
—
—
—
10
53
165
1769
13
92
119
1221
Diabetes non-insulin dependent
T90 [2002001131]
9.4e-01
6.4e-01
—
—
8.4e-01
6.5e-01
1.7e-01
cases:12.38%
controls:5.25%
cases:6.93%
controls:3.76%
—
—
—
—
cases:2.51%
controls:1.10%
cases:7.43%
controls:4.01%
cases:10.61%
controls:9.06%
25
106
177
1914
14
76
188
1944
—
—
5
22
194
1986
13
73
162
1749
14
119
118
1194
Internal Medicine
11 [38004456]
4.4e-01
5.6e-01
7.1e-01
1.0e+50
1.1e+00
8.9e-01
5.5e-01
cases:25.25%
controls:17.92%
cases:11.88%
controls:7.13%
cases:2.48%
controls:1.24%
cases:3.96%
controls:0.00%
cases:3.02%
controls:1.00%
cases:13.71%
controls:6.15%
cases:21.97%
controls:13.94%
51
362
151
1658
24
144
178
1876
5
25
197
1995
8
0
194
2020
6
20
193
1988
24
112
151
1710
29
183
103
1130
ciprofloxacin; oral, parenteral
J01MA02 [21603009]
8.6e-01
6.8e-01
—
—
—
—
4.7e-01
cases:11.88%
controls:5.40%
cases:3.47%
controls:1.78%
—
—
—
—
—
—
—
—
cases:7.58%
controls:4.87%
24
109
178
1911
7
36
195
1984
—
—
—
—
10
64
122
1249
Albumin [Presence] in Urine by Test strip
50949-7 [3029937]
-1.9e-02
-2.4e-01
—
—
—
1.5e-01
8.6e-01
cases:8.42%
controls:8.56%
cases:2.97%
controls:3.76%
—
—
—
—
—
—
cases:4.00%
controls:3.46%
cases:17.42%
controls:8.23%
17
173
185
1847
6
76
196
1944
—
—
—
7
63
168
1759
23
108
109
1205
prednisolone; oral, parenteral
H02AB06 [21602734]
8.4e-01
-2.3e-02
—
—
—
6.1e-01
6.3e-01
cases:18.32%
controls:8.86%
cases:4.46%
controls:4.55%
—
—
—
—
—
—
cases:8.00%
controls:4.50%
cases:17.42%
controls:10.13%
37
179
165
1841
9
92
193
1928
—
—
—
14
82
161
1740
23
133
109
1180
Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]
2.6e-01
5.1e-01
—
—
—
1.8e-01
8.3e-01
cases:15.84%
controls:12.72%
cases:5.94%
controls:3.66%
—
—
—
—
—
—
cases:4.57%
controls:3.84%
cases:18.94%
controls:9.22%
32
257
170
1763
12
74
190
1946
—
—
—
8
70
167
1752
25
121
107
1192
prednisolone
A07EA01 [21600653]
8.2e-01
-2.3e-02
—
—
—
6.1e-01
6.3e-01
cases:18.32%
controls:9.01%
cases:4.46%
controls:4.55%
—
—
—
—
—
—
cases:8.00%
controls:4.50%
cases:17.42%
controls:10.13%
37
182
165
1838
9
92
193
1928
—
—
—
14
82
161
1740
23
133
109
1180
Physical Medicine And Rehabilitation
25 [38004468]
8.1e-01
5.7e-01
—
—
—
3.3e-01
6.9e-01
cases:13.37%
controls:6.44%
cases:3.96%
controls:2.28%
—
—
—
—
—
—
cases:4.00%
controls:2.91%
cases:9.85%
controls:5.18%
27
130
175
1890
8
46
194
1974
—
—
—
7
53
168
1769
13
68
119
1245
diclofenac; oral, parenteral, rectal
M01AB05 [21603945]
7.9e-01
8.4e-01
9.3e-01
—
—
4.5e-01
7.1e-01
cases:25.25%
controls:13.32%
cases:9.41%
controls:4.31%
cases:2.48%
controls:0.99%
—
—
—
—
cases:6.29%
controls:4.12%
cases:20.45%
controls:11.20%
51
269
151
1751
19
87
183
1933
5
20
197
2000
—
—
11
75
164
1747
27
147
105
1166
cetirizine; oral
R06AE07 [21603497]
7.8e-01
7.0e-01
—
—
—
4.0e-01
7.7e-01
cases:13.37%
controls:6.63%
cases:6.44%
controls:3.32%
—
—
—
—
—
—
cases:5.14%
controls:3.51%
cases:12.88%
controls:6.40%
27
134
175
1886
13
67
189
1953
—
—
—
9
64
166
1758
17
84
115
1229
tizanidine; oral
M03BX02 [21604116]
7.3e-01
7.0e-01
—
—
—
8.6e-01
6.4e-01
cases:25.74%
controls:14.36%
cases:8.42%
controls:4.36%
—
—
—
—
—
—
cases:9.71%
controls:4.34%
cases:18.94%
controls:10.97%
52
290
150
1730
17
88
185
1932
—
—
—
17
79
158
1743
25
144
107
1169
doxycycline; oral, parenteral
J01AA02 [21602800]
6.8e-01
4.1e-01
—
—
—
4.5e-01
7.0e-01
cases:21.78%
controls:12.33%
cases:3.96%
controls:2.67%
—
—
—
—
—
—
cases:5.14%
controls:3.35%
cases:18.94%
controls:10.43%
44
249
158
1771
8
54
194
1966
—
—
—
9
61
166
1761
25
137
107
1176
etoricoxib; oral
M01AH05 [21603996]
6.6e-01
6.7e-01
9.8e-01
—
—
5.9e-01
6.3e-01
cases:31.68%
controls:19.41%
cases:13.86%
controls:7.62%
cases:2.48%
controls:0.94%
—
—
—
—
cases:12.00%
controls:7.03%
cases:29.55%
controls:18.28%
64
392
138
1628
28
154
174
1866
5
19
197
2001
—
—
21
128
154
1694
39
240
93
1073
Emergency Room Visit
ER [9203]
5.4e-01
6.6e-01
8.9e-01
1.0e+50
—
5.9e-01
4.7e-01
cases:42.08%
controls:29.65%
cases:13.86%
controls:7.67%
cases:2.97%
controls:1.24%
cases:11.39%
controls:0.00%
—
—
cases:12.57%
controls:7.35%
cases:29.55%
controls:20.72%
85
599
117
1421
28
155
174
1865
6
25
196
1995
23
0
179
2020
—
22
134
153
1688
39
272
93
1041
ibuprofen
R02AX02 [1588667]
5.4e-01
3.9e-01
1.8e-01
—
8.2e-01
1.9e-01
1.8e-01
cases:52.48%
controls:39.21%
cases:22.28%
controls:16.29%
cases:2.48%
controls:2.08%
—
—
cases:4.52%
controls:2.04%
cases:18.29%
controls:15.64%
cases:38.64%
controls:34.42%
106
792
96
1228
45
329
157
1691
5
42
197
1978
—
9
41
190
1967
32
285
143
1537
51
452
81
861
ibuprofen; oral, parenteral, rectal
M01AE01 [21603967]
5.4e-01
3.9e-01
1.8e-01
—
8.2e-01
1.9e-01
1.8e-01
cases:52.48%
controls:39.21%
cases:22.28%
controls:16.29%
cases:2.48%
controls:2.08%
—
—
cases:4.52%
controls:2.04%
cases:18.29%
controls:15.64%
cases:38.64%
controls:34.42%
106
792
96
1228
45
329
157
1691
5
42
197
1978
—
9
41
190
1967
32
285
143
1537
51
452
81
861
Anesthesiology Critical Care Medicine
OMOP4821991 [45756751]
1.5e+00
-1.0e+50
—
—
—
—
1.7e+00
cases:2.97%
controls:0.69%
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
cases:3.79%
controls:0.69%
6
14
196
2006
0
6
202
2014
—
—
—
—
5
9
127
1304
bisoprolol and thiazides
C07BB07 [21601714]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.64%
cases:0.00%
controls:0.25%
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
0
13
202
2007
0
5
202
2015
—
—
—
0
5
175
1817
—
Health maint/preventive medicine
A98 [2002000231]
1.6e-01
2.0e-01
4.6e-01
—
4.7e-01
1.6e-01
3.1e-01
cases:55.94%
controls:51.98%
cases:44.06%
controls:39.21%
cases:11.39%
controls:7.52%
—
—
cases:12.06%
controls:7.87%
cases:44.57%
controls:40.61%
cases:66.67%
controls:59.48%
113
1050
89
970
89
792
113
1228
23
152
179
1868
—
24
158
175
1850
78
740
97
1082
88
781
44
532
Colonoscopy Study observation
28023-0 [3022145]
3.6e-01
—
—
—
—
—
8.1e-02
cases:4.95%
controls:3.51%
—
—
—
—
—
—
—
—
—
—
cases:3.79%
controls:3.50%
10
71
192
1949
—
—
—
—
—
5
46
127
1267
citalopram; oral, parenteral
N06AB04 [21604712]
9.2e-01
—
-1.0e+50
—
—
—
—
cases:4.95%
controls:2.03%
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
10
41
192
1979
—
0
9
202
2011
—
—
—
—
Ultrasound examination of lower leg veins
PH2AE [2001309451]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
0
7
175
1815
—
magnesium hydroxide; oral
A02AA04 [21600052]
1.4e+00
—
-1.0e+50
—
-1.0e+50
—
—
cases:2.48%
controls:0.64%
—
—
cases:0.00%
controls:0.25%
—
—
cases:0.00%
controls:0.25%
—
—
—
—
5
13
197
2007
—
0
5
202
2015
—
0
5
199
2003
—
—
pseudoephedrine, combinations; oral
R01BA52 [21603213]
-2.9e-02
6.1e-02
-1.0e+50
—
-1.0e+50
-5.7e-02
6.7e-01
cases:11.39%
controls:11.68%
cases:3.47%
controls:3.27%
cases:0.00%
controls:0.64%
—
—
cases:0.00%
controls:0.40%
cases:3.43%
controls:3.62%
cases:15.15%
controls:8.38%
23
236
179
1784
7
66
195
1954
0
13
202
2007
—
0
8
199
2000
6
66
169
1756
20
110
112
1203
Struck by thrown, projected or falling object(s)
W20 [45756258]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
202
2012
—
—
—
—
—
—
dexamethasone
D10AA03 [21602286]
7.4e-01
—
—
—
—
1.7e+00
—
cases:3.47%
controls:1.68%
—
—
—
—
—
—
—
—
cases:2.86%
controls:0.55%
—
—
7
34
195
1986
—
—
—
—
5
10
170
1812
—
Transrectal gold marker implantation in prostate under ultrasound guidance
KE3AT [2001306393]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.25%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
202
2015
—
—
—
—
—
—
Endovascular dilatation of coronary arteries (PTCA)
FN1AT [2001303062]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.25%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
202
2015
—
—
—
—
—
—
Atherosclerotic heart disease
I25.1 [45596196]
2.7e-01
4.9e-01
—
1.0e+50
1.5e+00
6.6e-01
5.2e-01
cases:5.45%
controls:4.21%
cases:4.46%
controls:2.77%
—
—
cases:3.96%
controls:0.00%
cases:2.51%
controls:0.60%
cases:4.57%
controls:2.41%
cases:9.09%
controls:5.64%
11
85
191
1935
9
56
193
1964
—
8
0
194
2020
5
12
194
1996
8
44
167
1778
12
74
120
1239
levodopa, decarboxylase inhibitor and COMT inhibitor; oral
N04BA03 [21604466]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.25%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
202
2015
—
—
—
—
—
—
Visual disturbance other
F05 [2002000403]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
6
132
1307
Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma
33762-6 [3029187]
-1.5e-02
7.6e-01
—
—
—
6.9e-02
3.5e-01
cases:6.93%
controls:7.03%
cases:5.94%
controls:2.87%
—
—
—
—
—
—
cases:4.57%
controls:4.28%
cases:12.12%
controls:8.83%
14
142
188
1878
12
58
190
1962
—
—
—
8
78
167
1744
16
116
116
1197
Pilonidal cyst without abscess
L05.9 [45581935]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
5
132
1308
Implantation of transvenous cardiac pacemaker with atrial and ventricular electrodes
FPE20 [2001303170]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
0
8
132
1305
Retained molar with obstruction in the lower jaw
K01.17 [2000502662]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
5
132
1308
Reparation of dental prosthesis without impressions
SPF00 [2001310544]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
202
2014
—
—
—
—
—
—
Sprain and strain of wrist
S63.5 [45598382]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.25%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.76%
0
5
202
2015
—
—
—
—
—
0
10
132
1303
cromoglicic acid
S01GX01 [21605085]
6.5e-01
—
—
—
—
—
9.1e-01
cases:4.46%
controls:2.38%
—
—
—
—
—
—
—
—
—
—
cases:5.30%
controls:2.21%
9
48
193
1972
—
—
—
—
—
7
29
125
1284
Fracture of upper end of ulna
S52.0 [45588185]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.25%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
202
2015
—
—
—
—
—
—
Palliative care
Z51.5 [45547323]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
cases:0.00%
controls:1.22%
—
—
—
—
—
0
5
175
1817
0
16
132
1297
Sensorineural hearing loss, bilateral
H90.3 [45576850]
5.1e-01
—
—
—
—
—
6.8e-01
cases:3.96%
controls:2.43%
—
—
—
—
—
—
—
—
—
—
cases:4.55%
controls:2.36%
8
49
194
1971
—
—
—
—
—
6
31
126
1282
Hepatitis E virus Ab [Presence] in Serum
13294-4 [3006922]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
202
2012
—
—
—
—
—
—
rosuvastatin; oral
C10AA07 [21601862]
4.9e-01
5.0e-01
8.1e-01
—
-2.4e-01
4.6e-01
3.0e-01
cases:11.39%
controls:7.33%
cases:12.38%
controls:7.92%
cases:4.46%
controls:2.03%
—
—
cases:2.51%
controls:3.19%
cases:13.14%
controls:8.73%
cases:15.91%
controls:12.34%
23
148
179
1872
25
160
177
1860
9
41
193
1979
—
5
64
194
1944
23
159
152
1663
21
162
111
1151
Polycythaemia vera
D45 [45595761]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.25%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
202
2015
—
—
—
—
—
—
dexbrompheniramine, combinations
R06AB56 [21603469]
2.5e-01
-1.0e+50
—
—
—
—
—
cases:2.48%
controls:1.93%
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
5
39
197
1981
0
9
202
2011
—
—
—
—
—
Flank/axilla symptom/complaint
L05 [2002000630]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.59%
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.22%
0
12
202
2008
0
7
202
2013
—
—
—
—
0
16
132
1297
Valproate [Moles/volume] in Serum or Plasma
14946-8 [3009466]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
6
132
1307
Alzheimer disease with late onset
G30.1 [45552521]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.25%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
202
2015
—
—
—
—
—
—
insulin aspart; parenteral
A10AB05 [21600719]
-4.2e-01
—
—
—
—
—
—
cases:2.48%
controls:3.71%
—
—
—
—
—
—
—
—
—
—
—
—
5
75
197
1945
—
—
—
—
—
—
Emergency treatment
SGA01 [2001310379]
2.3e-01
—
—
—
—
—
—
cases:4.46%
controls:3.56%
—
—
—
—
—
—
—
—
—
—
—
—
9
72
193
1948
—
—
—
—
—
—
Health check-up performed during second study year in students of upper secondary schools, vocational schools etc.
SPAT1364 [2001700465]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
202
2014
—
—
—
—
—
—
Psychiatry
26 [38004469]
6.0e-01
6.0e-01
—
—
5.0e-01
8.4e-01
6.5e-01
cases:13.37%
controls:7.82%
cases:7.43%
controls:4.21%
—
—
—
—
cases:2.51%
controls:1.54%
cases:6.86%
controls:3.07%
cases:11.36%
controls:6.25%
27
158
175
1862
15
85
187
1935
—
—
5
31
194
1977
12
56
163
1766
15
82
117
1231
Colonoscopy
SPAT1131 [2001700232]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
202
2013
—
—
—
—
—
—
carbamazepine; oral, rectal
N03AF01 [21604417]
-1.0e+50
-1.0e+50
-1.0e+50
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.74%
cases:0.00%
controls:0.45%
cases:0.00%
controls:0.25%
—
—
—
—
cases:0.00%
controls:0.55%
cases:0.00%
controls:0.38%
0
15
202
2005
0
9
202
2011
0
5
202
2015
—
—
0
10
175
1812
0
5
132
1308
Endomysium IgG Ab [Titer] in Serum
49726-3 [3032773]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
202
2010
—
—
—
—
—
—
pH of Capillary blood
2745-8 [3009343]
4.2e-01
—
—
—
—
—
—
cases:2.48%
controls:1.63%
—
—
—
—
—
—
—
—
—
—
—
—
5
33
197
1987
—
—
—
—
—
—
Infectious disease other/NOS
A78 [2002000212]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
0
6
202
2014
—
—
—
—
—
0
5
132
1308
Methemoglobin/Hemoglobin.total in Blood
2614-6 [3007930]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
0
9
175
1813
—
Sialoadenitis
K11.2 [45586705]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.25%
—
—
—
—
—
—
—
—
—
—
—
0
5
202
2015
—
—
—
—
—
warfarin; oral, parenteral
B01AA03 [21600965]
2.9e-01
-1.5e-01
—
—
—
—
1.3e-01
cases:4.95%
controls:3.76%
cases:2.48%
controls:2.87%
—
—
—
—
—
—
—
—
cases:3.79%
controls:3.35%
10
76
192
1944
5
58
197
1962
—
—
—
—
5
44
127
1269
Haptoglobin [Mass/volume] in Serum or Plasma
4542-7 [3012336]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
cases:0.00%
controls:1.60%
—
—
—
—
—
0
6
175
1816
0
21
132
1292
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
2.4e-01
5.6e-01
1.4e+00
—
—
3.1e-01
2.2e-01
cases:25.74%
controls:21.49%
cases:14.36%
controls:8.76%
cases:3.47%
controls:0.84%
—
—
—
—
cases:12.00%
controls:9.11%
cases:25.00%
controls:21.17%
52
434
150
1586
29
177
173
1843
7
17
195
2003
—
—
21
166
154
1656
33
278
99
1035
Intentional self-poisoning by and exposure to other and unspecified chemicals and noxious substances
X69 [45585661]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.25%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
202
2015
—
—
—
—
—
—
Split tooth for reasons other than trauma
K03.82 [2000502700]
1.3e-01
—
—
—
-1.0e+50
—
1.1e-03
cases:2.97%
controls:2.62%
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
cases:12.12%
controls:12.11%
6
53
196
1967
—
—
—
0
12
199
1996
—
16
159
116
1154
azithromycin
S01AA26 [21603577]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
5
132
1308
celecoxib
L01XX33 [21603805]
1.1e+00
—
—
—
—
-1.0e+50
—
cases:3.47%
controls:1.24%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
7
25
195
1995
—
—
—
—
0
5
175
1817
—
Ulcer of lower limb, not elsewhere classified
L97 [45591659]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
0
6
175
1816
—
Streptococcus sp identified in Isolate by Organism specific culture
43389-6 [3042975]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
202
2014
—
—
—
—
—
—
Place of Employment-Worksite
18 [581475]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
cases:0.00%
controls:0.71%
cases:0.00%
controls:1.37%
—
0
9
202
2011
—
—
—
0
13
175
1809
0
18
132
1295
Simple examination of mouth
SAA01 [2001310274]
6.6e-02
2.1e-01
—
—
6.1e-01
2.7e-01
2.0e-01
cases:32.67%
controls:31.24%
cases:13.86%
controls:11.53%
—
—
—
—
cases:3.52%
controls:1.94%
cases:16.57%
controls:13.12%
cases:34.85%
controls:30.39%
66
631
136
1389
28
233
174
1787
—
—
7
39
192
1969
29
239
146
1583
46
399
86
914
Brachial plexus disorders
G54.0 [45586302]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
202
2014
—
—
—
—
—
—
Pure hypercholesterolaemia
E78.0 [45542771]
9.9e-02
2.7e-01
—
—
—
—
1.8e-01
cases:4.95%
controls:4.50%
cases:2.97%
controls:2.28%
—
—
—
—
—
—
—
—
cases:8.33%
controls:7.08%
10
91
192
1929
6
46
196
1974
—
—
—
—
11
93
121
1220
Spirometry at the office
SPAT1059 [2001700160]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.69%
—
—
—
—
—
—
0
9
132
1304
levomepromazine; oral, parenteral
N05AA02 [21604493]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
—
0
6
202
2014
—
—
—
—
—
Fracture of scapula
S42.1 [45573538]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.25%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
202
2015
—
—
—
—
—
—
Chloride [Moles/volume] in Blood
2069-3 [3018572]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
0
7
202
2013
—
—
—
—
—
0
7
132
1306
dexamethasone
S03BA01 [21605201]
6.0e-01
—
—
—
—
1.5e+00
—
cases:4.95%
controls:2.77%
—
—
—
—
—
—
—
—
cases:3.43%
controls:0.77%
—
—
10
56
192
1964
—
—
—
—
6
14
169
1808
—
hydrocortisone aceponate
D07AC16 [21602135]
4.3e-01
9.8e-01
—
—
—
7.3e-01
6.8e-01
cases:9.90%
controls:6.68%
cases:5.94%
controls:2.33%
—
—
—
—
—
—
cases:4.00%
controls:1.98%
cases:12.12%
controls:6.55%
20
135
182
1885
12
47
190
1973
—
—
—
7
36
168
1786
16
86
116
1227
Concise certificate
WZA00 [2001310879]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
—
—
—
0
11
132
1302
hydrocortisone
S02BA01 [21605166]
4.6e-01
6.9e-01
—
—
—
6.7e-01
5.8e-01
cases:8.42%
controls:5.50%
cases:3.96%
controls:2.03%
—
—
—
—
—
—
cases:2.86%
controls:1.48%
cases:9.85%
controls:5.79%
17
111
185
1909
8
41
194
1979
—
—
—
5
27
170
1795
13
76
119
1237
Dermatitis, unspecified
L30.9 [45572271]
4.6e-01
—
—
—
—
6.3e-01
1.1e+00
cases:4.95%
controls:3.17%
—
—
—
—
—
—
—
—
cases:2.86%
controls:1.54%
cases:9.09%
controls:3.35%
10
64
192
1956
—
—
—
—
5
28
170
1794
12
44
120
1269
prednisolone
S03BA02 [21605202]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
—
—
—
0
16
202
2004
—
—
—
—
—
insulins and analogues for injection, intermediate-acting - combinations; parenteral
A10AC30 [21600727]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.14%
cases:0.00%
controls:0.64%
—
—
—
—
—
—
cases:0.00%
controls:0.66%
cases:0.00%
controls:1.07%
0
23
202
1997
0
13
202
2007
—
—
—
0
12
175
1810
0
14
132
1299
Dermatological photography
XQ848 [2001310110]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
0
8
132
1305
Repair of inguinal hernia using prosthetic material
JAB30 [2001304393]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
0
7
202
2013
—
—
—
—
—
Promyelocytes/Leukocytes in Blood
26524-9 [3021440]
8.0e-01
—
—
—
-1.0e+50
8.8e-01
—
cases:3.47%
controls:1.58%
—
—
—
—
—
—
cases:0.00%
controls:0.30%
cases:2.86%
controls:1.21%
—
—
7
32
195
1988
—
—
—
0
6
199
2002
5
22
170
1800
—
Impotence of organic origin
N48.4 [45558161]
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
cases:2.86%
controls:0.33%
—
—
—
—
—
—
—
5
6
170
1816
—
telmisartan; oral
C09CA07 [21601830]
—
—
-1.0e+50
—
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.25%
—
—
cases:0.00%
controls:0.25%
—
—
—
—
—
—
0
5
202
2015
—
0
5
199
2003
—
—
Ear discharge
H04 [2002000478]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
202
2011
—
—
—
—
—
—
Periodontal treatment by dental hygienist, extensive
SDE03 [2001310351]
—
—
—
—
—
—
7.8e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.55%
controls:2.13%
—
—
—
—
—
—
6
28
126
1285
dextromethorphan, combinations; oral
N07XX59 [43534835]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
202
2012
—
—
—
—
—
—
Oligoclonal Bands IgG [Presence] in Cerebral spinal fluid by Isoelectric focusing
56764-4 [40759883]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
202
2013
—
—
—
—
—
—
moxonidine; oral
C02AC05 [21600401]
1.2e+00
—
—
—
—
1.8e+00
—
cases:2.48%
controls:0.74%
—
—
—
—
—
—
—
—
cases:2.86%
controls:0.49%
—
—
5
15
197
2005
—
—
—
—
5
9
170
1813
—
Polysomnography panel
90568-7 [1002224]
3.4e-01
—
—
—
—
-1.0e+50
1.1e+00
cases:2.48%
controls:1.78%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
cases:6.06%
controls:2.13%
5
36
197
1984
—
—
—
—
0
11
175
1811
8
28
124
1285
Other dental caries
K02.8 [45586690]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
202
2013
—
—
—
—
—
—
Zoster [herpes zoster]
B02 [45552205]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
13
202
2007
—
—
—
—
—
—
hydrocortisone and antiinfectives
S02CA03 [21605175]
7.9e-01
—
—
—
—
—
4.9e-01
cases:4.46%
controls:2.08%
—
—
—
—
—
—
—
—
—
—
cases:3.79%
controls:2.36%
9
42
193
1978
—
—
—
—
—
5
31
127
1282
Cathetrisation of vein
TPH04 [2001309597]
2.5e-01
—
-1.0e+50
—
-1.0e+50
-1.0e+50
3.7e-01
cases:4.95%
controls:3.91%
—
—
cases:0.00%
controls:0.25%
—
—
cases:0.00%
controls:0.25%
cases:0.00%
controls:1.43%
cases:4.55%
controls:3.20%
10
79
192
1941
—
0
5
202
2015
—
0
5
199
2003
0
26
175
1796
6
42
126
1271
Suture or reinsertation of rotator cuff of shoulder
NBL00 [2001307341]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
0
7
132
1306
Seborrhoeic keratosis
L82 [45548208]
4.4e-01
—
—
—
—
—
—
cases:3.96%
controls:2.57%
—
—
—
—
—
—
—
—
—
—
—
—
8
52
194
1968
—
—
—
—
—
—
Scabies
B86 [45561769]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
—
0
6
202
2014
—
—
—
—
—
Catheterisation instruction
TKC22 [2001306021]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
202
2013
—
—
—
—
—
—
Periodontitis pronounced
K05.31 [2000502729]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:1.04%
—
—
—
—
—
—
cases:0.00%
controls:1.32%
—
—
—
0
21
202
1999
—
—
—
0
24
175
1798
—
Bilateral vasectomy or ligature of vas deferens
KFD46 [2001306215]
1.2e+00
—
—
—
—
—
-1.0e+50
cases:2.48%
controls:0.74%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
5
15
197
2005
—
—
—
—
—
0
5
132
1308
Cardiovascular stress test using bicycle ergometer
26046004 [4094501]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
0
9
202
2011
—
—
—
0
6
175
1816
—
betamethasone
C05AA05 [21601610]
7.6e-01
8.8e-01
-1.0e+50
—
—
9.7e-01
2.3e-01
cases:11.88%
controls:5.94%
cases:5.45%
controls:2.33%
cases:0.00%
controls:0.74%
—
—
—
—
cases:6.29%
controls:2.47%
cases:9.09%
controls:7.39%
24
120
178
1900
11
47
191
1973
0
15
202
2005
—
—
11
45
164
1777
12
97
120
1216
Urea [Moles/volume] in Serum or Plasma
22664-7 [3020779]
1.7e-02
—
—
—
—
7.9e-01
1.8e-01
cases:2.97%
controls:2.92%
—
—
—
—
—
—
—
—
cases:2.86%
controls:1.32%
cases:3.79%
controls:3.20%
6
59
196
1961
—
—
—
—
5
24
170
1798
5
42
127
1271
clidinium and psycholeptics
A03CA02 [21600204]
1.4e+00
—
—
—
—
—
—
cases:2.48%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
5
13
197
2007
—
—
—
—
—
—
Psychiatric consultation in another specialty
IAZ97 [2001304038]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
5
132
1308
Shoulder lesion, unspecified
M75.9 [45557986]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.59%
cases:0.00%
controls:0.25%
—
—
—
—
—
—
—
—
—
—
0
12
202
2008
0
5
202
2015
—
—
—
—
—
tamsulosin; oral
G04CA02 [21602669]
5.5e-01
5.0e-01
4.9e-01
—
—
2.0e-01
1.4e-01
cases:10.89%
controls:6.58%
cases:7.43%
controls:4.65%
cases:2.48%
controls:1.53%
—
—
—
—
cases:5.71%
controls:4.72%
cases:9.09%
controls:8.00%
22
133
180
1887
15
94
187
1926
5
31
197
1989
—
—
10
86
165
1736
12
105
120
1208
Other primary coxarthrosis
M16.1 [45591741]
1.1e+00
—
-1.0e+50
—
—
—
—
cases:3.96%
controls:1.39%
—
—
cases:0.00%
controls:0.25%
—
—
—
—
—
—
—
—
8
28
194
1992
—
0
5
202
2015
—
—
—
—
COVID-19, virus not identified
U07.2 [45756094]
2.0e-01
5.7e-01
-1.0e+50
—
—
1.7e-01
2.9e-01
cases:6.44%
controls:5.35%
cases:3.47%
controls:1.98%
cases:0.00%
controls:0.30%
—
—
—
—
cases:2.86%
controls:2.41%
cases:6.82%
controls:5.18%
13
108
189
1912
7
40
195
1980
0
6
202
2014
—
—
5
44
170
1778
9
68
123
1245
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
3.8e-01
7.7e-01
1.0e+00
—
8.0e-01
1.8e-01
4.8e-01
cases:19.31%
controls:14.11%
cases:12.38%
controls:6.14%
cases:2.97%
controls:1.09%
—
—
cases:2.51%
controls:1.15%
cases:7.43%
controls:6.26%
cases:21.21%
controls:14.32%
39
285
163
1735
25
124
177
1896
6
22
196
1998
—
5
23
194
1985
13
114
162
1708
28
188
104
1125
Chronic viral hepatitis C
B18.2 [45590846]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
0
7
202
2013
—
—
—
—
0
7
132
1306
Presbycusis
H91.1 [45591444]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.45%
cases:0.00%
controls:0.40%
—
—
—
—
—
—
cases:0.00%
controls:0.27%
cases:0.00%
controls:0.61%
0
9
202
2011
0
8
202
2012
—
—
—
0
5
175
1817
0
8
132
1305
naproxcinod
M01AE18 [40254094]
-2.8e-01
2.3e-01
—
—
-1.0e+50
2.7e-01
4.3e-01
cases:6.44%
controls:8.32%
cases:2.48%
controls:1.98%
—
—
—
—
cases:0.00%
controls:0.30%
cases:2.86%
controls:2.20%
cases:9.09%
controls:6.09%
13
168
189
1852
5
40
197
1980
—
—
0
6
199
2002
5
40
170
1782
12
80
120
1233
vedolizumab; parenteral
L04AG05 [955244]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
0
5
175
1817
—
solifenacin; oral
G04BD08 [21602641]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.35%
cases:0.00%
controls:0.25%
—
—
—
—
—
—
—
—
—
—
0
7
202
2013
0
5
202
2015
—
—
—
—
—
Achilles tendinitis
M76.6 [45596682]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
—
0
6
202
2014
—
—
—
—
—
hydrocortisone and antiseptics
D07BA04 [21602146]
8.3e-01
1.3e+00
—
—
—
—
8.4e-01
cases:3.47%
controls:1.53%
cases:2.48%
controls:0.69%
—
—
—
—
—
—
—
—
cases:3.79%
controls:1.68%
7
31
195
1989
5
14
197
2006
—
—
—
—
5
22
127
1291
Sprain and strain of elbow
S53.4 [45549825]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.25%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
202
2015
—
—
—
—
—
—
Personal history of COVID-19, unspecified
U08.9 [710719]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
202
2013
—
—
—
—
—
—
Tear of meniscus, current
S83.2 [45555441]
1.2e+00
—
—
—
—
—
—
cases:2.48%
controls:0.74%
—
—
—
—
—
—
—
—
—
—
—
—
5
15
197
2005
—
—
—
—
—
—
indapamide; oral
C03BA11 [21601499]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
0
6
175
1816
—
Leukocytes [#/volume] in Urine
30405-5 [3018095]
2.9e-01
7.3e-01
1.6e+00
1.0e+50
1.3e+00
-9.3e-02
1.2e-01
cases:11.88%
controls:9.16%
cases:8.42%
controls:4.26%
cases:3.47%
controls:0.69%
cases:3.47%
controls:0.00%
cases:2.51%
controls:0.70%
cases:4.57%
controls:4.99%
cases:12.88%
controls:11.58%
24
185
178
1835
17
86
185
1934
7
14
195
2006
7
0
195
2020
5
14
194
1994
8
91
167
1731
17
152
115
1161
Other gastroenteritis and colitis of infectious and unspecified origin
A09 [45605189]
4.0e-01
—
—
—
—
—
6.4e-01
cases:4.46%
controls:3.02%
—
—
—
—
—
—
—
—
—
—
cases:4.55%
controls:2.44%
9
61
193
1959
—
—
—
—
—
6
32
126
1281
Treatment of reopened or infected surgical wound
SPAT1144 [2001700245]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
5
132
1308
Glomerular basement membrane Ab [Units/volume] in Serum
49774-3 [3032700]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
0
7
132
1306
Implantation of vascular injection port
TPX10 [2001309608]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.25%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
202
2015
—
—
—
—
—
—
Convalescence following surgery
Z54.0 [45576164]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
5
132
1308
Sarcoidosis of lung with sarcoidosis of lymph nodes
D86.2 [45586127]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
0
6
202
2014
—
—
—
—
—
0
5
132
1308
Taking care of patient’s/customer’s hygiene
SPAT1137 [2001700238]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.25%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.69%
0
5
202
2015
—
—
—
—
—
0
9
132
1304
Actinic keratosis
L57.0 [45591640]
—
—
—
—
—
—
1.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.30%
controls:1.52%
—
—
—
—
—
—
7
20
125
1293
Adhesive capsulitis of shoulder
M75.0 [45533931]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.59%
cases:0.00%
controls:0.35%
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
0
12
202
2008
0
7
202
2013
—
—
—
0
7
175
1815
—
Implementation of physical therapy rehabilitation plan
SPAT1223 [2001700324]
1.7e-01
—
—
—
—
—
5.8e-01
cases:4.95%
controls:4.21%
—
—
—
—
—
—
—
—
—
—
cases:5.30%
controls:3.05%
10
85
192
1935
—
—
—
—
—
7
40
125
1273
epinephrine
S01EA01 [21603673]
8.8e-01
—
—
—
—
—
—
cases:2.48%
controls:1.04%
—
—
—
—
—
—
—
—
—
—
—
—
5
21
197
1999
—
—
—
—
—
—
Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction
14804-9 [3022250]
-2.9e-02
1.5e-01
—
—
—
—
—
cases:3.47%
controls:3.56%
cases:2.48%
controls:2.13%
—
—
—
—
—
—
—
—
—
—
7
72
195
1948
5
43
197
1977
—
—
—
—
—
Normetanephrine [Moles/volume] in Serum or Plasma
25489-6 [3026179]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
202
2013
—
—
—
—
—
—
Depressive disorder
P76 [2002000870]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
0
7
132
1306
Type 1 diabetes mellitus, With unspecified complications
E10.8 [45552384]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.25%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
0
5
202
2015
—
—
—
—
—
0
6
132
1307
Stomach Pathology biopsy report
66114-0 [40768797]
-3.8e-01
8.8e-01
—
—
—
—
—
cases:2.48%
controls:3.56%
cases:2.48%
controls:1.04%
—
—
—
—
—
—
—
—
—
—
5
72
197
1948
5
21
197
1999
—
—
—
—
—
Iron [Moles/volume] in Serum or Plasma
14798-3 [3022948]
3.5e-01
7.4e-01
—
—
—
3.5e-01
3.1e-01
cases:5.45%
controls:3.91%
cases:3.96%
controls:1.93%
—
—
—
—
—
—
cases:2.86%
controls:2.03%
cases:6.82%
controls:5.10%
11
79
191
1941
8
39
194
1981
—
—
—
5
37
170
1785
9
67
123
1246
Treatment plan or consultation
WZC00 [2001310885]
1.6e-01
7.6e-01
-1.0e+50
—
-1.0e+50
9.9e-01
2.4e-01
cases:7.43%
controls:6.39%
cases:4.95%
controls:2.38%
cases:0.00%
controls:0.30%
—
—
cases:0.00%
controls:0.25%
cases:5.14%
controls:1.98%
cases:8.33%
controls:6.70%
15
129
187
1891
10
48
192
1972
0
6
202
2014
—
0
5
199
2003
9
36
166
1786
11
88
121
1225
Viral intestinal infection, unspecified
A08.4 [45576230]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
5
132
1308
tacrolimus
D11AH01 [21602338]
1.1e+00
—
—
—
—
—
—
cases:2.97%
controls:0.99%
—
—
—
—
—
—
—
—
—
—
—
—
6
20
196
2000
—
—
—
—
—
—
Sensorineural hearing loss, unilateral with unrestricted hearing on the contralateral side
H90.4 [45572067]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
0
5
175
1817
—
Chronic ischaemic heart disease
I25 [45581765]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
cases:0.00%
controls:0.69%
—
—
—
—
—
0
6
175
1816
0
9
132
1304
Migraine without aura [common migraine]
G43.0 [45600784]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
202
2011
—
—
—
—
—
—
Anogenital (venereal) warts
A63.0 [45585929]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
6
132
1307
sulfasalazine; oral, rectal
A07EC01 [21600663]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
0
7
199
2001
—
—
Erythrocytes [Presence] in Urine
33051-4 [3045424]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
0
5
175
1817
—
Shortness of breath/dyspnoea
R02 [2002000883]
—
—
—
—
—
—
5.6e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.79%
controls:2.21%
—
—
—
—
—
—
5
29
127
1284
Fracture of metatarsal bone
S92.3 [45574912]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
5
132
1308
EKG study
11524-6 [3013512]
2.8e-01
1.9e-01
—
—
—
4.8e-01
3.9e-01
cases:11.88%
controls:9.21%
cases:5.45%
controls:4.55%
—
—
—
—
—
—
cases:5.71%
controls:3.62%
cases:16.67%
controls:11.96%
24
186
178
1834
11
92
191
1928
—
—
—
10
66
165
1756
22
157
110
1156
cough suppressants and expectorants
R05FB02 [21603442]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
202
2012
—
—
—
—
—
—
Sleep disorder, unspecified
G47.9 [45595948]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
0
5
175
1817
—
Laparoscopic dissection of iliac lymph nodes
PJD64 [2001309643]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.25%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
202
2015
—
—
—
—
—
—
Bacterial pneumonia, unspecified
J15.9 [45557621]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.25%
—
—
—
—
—
—
—
—
—
—
—
0
5
202
2015
—
—
—
—
—
Creatine [Moles/volume] in Urine
15046-6 [3022689]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
6
132
1307
hydrocortisone butyrate
D07AB02 [21602106]
4.3e-01
9.8e-01
—
—
—
7.3e-01
6.8e-01
cases:9.90%
controls:6.68%
cases:5.94%
controls:2.33%
—
—
—
—
—
—
cases:4.00%
controls:1.98%
cases:12.12%
controls:6.55%
20
135
182
1885
12
47
190
1973
—
—
—
7
36
168
1786
16
86
116
1227
Volume in Urine collected for unspecified duration
19153-6 [3004775]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
0
8
202
2012
—
—
—
—
0
6
175
1816
—
sumatriptan; nasal, oral, parenteral, rectal
N02CC01 [21604376]
—
—
-1.0e+50
—
—
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.25%
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
0
5
202
2015
—
—
0
15
175
1807
—
glimepiride; oral
A10BB12 [21600761]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
0
7
202
2013
—
—
—
—
0
5
132
1308
Periodontal treatment by dental hygienist, very extensive
SDE04 [2001310352]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
6
132
1307
orphenadrine, combinations
M03BC51 [21604113]
7.4e-01
—
—
—
—
—
—
cases:5.45%
controls:2.67%
—
—
—
—
—
—
—
—
—
—
—
—
11
54
191
1966
—
—
—
—
—
—
acetylsalicylic acid; oral, parenteral, rectal
N02BA01 [21604305]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
—
—
—
0
8
202
2012
—
—
—
—
Special examination, unspecified
Z01.9 [45576123]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
6
132
1307
gabapentin; oral
N02BF01 [955005]
5.3e-01
9.4e-01
—
—
—
1.1e+00
6.3e-01
cases:5.45%
controls:3.27%
cases:4.46%
controls:1.78%
—
—
—
—
—
—
cases:5.14%
controls:1.70%
cases:7.58%
controls:4.19%
11
66
191
1954
9
36
193
1984
—
—
—
9
31
166
1791
10
55
122
1258
Ocular fundus photography for diabetic retinopathy screening
CL2S4 [2001301465]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
202
2008
—
—
—
—
—
—
Free T4 and TSH panel - Serum or Plasma
24348-5 [3001019]
6.4e-01
-1.0e+50
—
—
—
—
—
cases:2.97%
controls:1.58%
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
—
—
—
6
32
196
1988
0
8
202
2012
—
—
—
—
—
Influenza virus B RNA [Presence] in Specimen by NAA with probe detection
40982-1 [3038288]
9.3e-01
—
—
—
—
—
1.8e-01
cases:5.45%
controls:2.23%
—
—
—
—
—
—
—
—
—
—
cases:4.55%
controls:3.81%
11
45
191
1975
—
—
—
—
—
6
50
126
1263
Operation for osteochondritis of knee, arthroscopic
NGF25 [2001308133]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.25%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
202
2015
—
—
—
—
—
—
pseudoephedrine; oral
R01BA02 [21603210]
7.4e-01
—
—
—
—
—
—
cases:5.94%
controls:2.92%
—
—
—
—
—
—
—
—
—
—
—
—
12
59
190
1961
—
—
—
—
—
—
Fracture of upper end of humerus
S42.2 [45544677]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
5
132
1308
Caries of cementum
K02.2 [45591568]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
0
5
175
1817
—
Lumbar spine MRI examination with high intensity magnet
NA3BG [2001307034]
—
—
—
—
—
—
1.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.30%
controls:1.37%
—
—
—
—
—
—
7
18
125
1295
promethazine, combinations
R06AD52 [21603489]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
202
2012
—
—
—
—
—
—
OLANZapine [Moles/volume] in Serum or Plasma
39484-1 [3040370]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
0
7
202
2013
—
—
—
—
—
0
5
132
1308
Release of median nerve
ACC51 [2001300642]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.79%
controls:0.53%
—
—
—
—
—
—
5
7
127
1306
Rheumatoid factor [Units/volume] in Serum or Plasma
11572-5 [3021614]
—
9.3e-01
—
—
—
—
7.9e-01
—
—
cases:2.97%
controls:1.19%
—
—
—
—
—
—
—
—
cases:6.82%
controls:3.20%
—
6
24
196
1996
—
—
—
—
9
42
123
1271
Assessment of need for medical rehabilitation
SPAT1215 [2001700316]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
202
2013
—
—
—
—
—
—
diclofenac; ointment
M02AA15 [21604051]
6.8e-01
—
—
—
—
—
1.3e+00
cases:6.44%
controls:3.37%
—
—
—
—
—
—
—
—
—
—
cases:6.06%
controls:1.75%
13
68
189
1952
—
—
—
—
—
8
23
124
1290
Excessive attrition of teeth
K03.0 [45601139]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
202
2011
—
—
—
—
—
—
Other erosion of teeth
K03.28 [2000502680]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.69%
0
6
202
2014
—
—
—
—
—
0
9
132
1304
Fracture of thumb
S62.5 [45598289]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.25%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
202
2015
—
—
—
—
—
—

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
74
70
15.94
72.46
2.1
1.6
5.69
4.88
u/l
0.40
63
57
151
394
11.61
66.03
6.4
2.2
13.48
15.41
nmol/l
2.63
151
374
172
1064
4.74
17.40
4.7
4.3
1.36
1.60
ug/l
1.27
165
970
26
46
6.32
14.54
2.3
1.3
183.48
173.80
pmol/l
0.16
26
46
118
636
3.00
13.50
3.1
2.7
0.64
0.72
ug/l
0.54
59
338
191
1471
5.10
10.13
5.0
3.9
1.82
1.91
mu/l
0.62
185
1369
30
82
4.11
10.13
1.7
1.3
—
—
—
0
0
77
410
2.40
8.01
2.8
5.5
—
—
—
0
0
101
613
2.27
7.66
2.0
1.9
92.31
94.54
pmol/l
0.21
61
335
113
723
2.25
7.49
6.0
9.6
1.21
1.20
mmol/l
1.77
99
643
45
195
2.67
7.14
2.1
1.7
3.42
3.61
mmol/l
0.44
35
132
127
892
2.11
6.18
4.4
3.4
—
7.08
—
0
13
124
867
2.08
6.07
6.0
7.3
0.59
0.60
e9/l
0.20
112
751
163
1272
2.35
5.93
8.7
9.1
75.15
79.03
u/l
0.43
157
1233
126
896
2.05
5.77
6.1
7.8
0.18
0.20
e9/l
0.93
114
793
123
868
2.04
5.74
6.0
7.4
0.04
0.04
e9/l
0.02
112
754
134
980
2.05
5.61
5.6
6.8
6.59
6.86
mmol/l
0.74
128
947
124
884
2.01
5.55
6.0
7.5
1.78
1.86
e9/l
0.53
113
786
11
15
7.68
5.21
1.3
1.1
19.94
26.93
ng/l
0.37
11
15
80
506
1.95
4.92
4.0
2.9
60.00
58.07
e6/l
0.01
65
376
60
347
2.03
4.73
1.3
1.4
2.48
2.65
g/l
0.42
43
243
177
1482
2.38
4.65
18.6
17.7
13.43
13.35
%
0.40
177
1469
56
321
2.02
4.51
2.4
2.2
2.57
2.93
mg/l
0.68
51
282
62
369
1.97
4.49
1.8
1.5
17.91
19.09
nmol/l
0.32
57
323
70
437
1.91
4.39
3.6
4.3
7.39
7.40
ph
0.83
50
305
62
374
1.94
4.30
1.2
1.4
0.66
0.84
u/ml
1.09
17
116
116
870
1.76
3.86
3.7
2.9
—
—
—
0
0
24
103
2.51
3.84
3.4
3.0
—
—
—
0
0
198
1813
3.37
3.75
16.7
12.3
—
—
—
0
0
124
956
1.75
3.67
8.9
11.2
4.27
4.17
e9/l
0.12
115
838
95
685
1.72
3.54
4.9
5.9
37.76
36.88
g/l
0.78
89
654
102
750
1.71
3.54
8.9
12.4
1.15
1.21
inr
0.46
78
629
110
833
1.69
3.37
3.6
3.1
0.00
0.00
estimate
-0.00
25
168
82
574
1.71
3.37
4.4
3.5
20.78
168.72
e6/l
1.20
67
405
19
78
2.58
3.32
1.3
1.2
33.02
134.57
u/ml
—
6
30
192
1727
2.64
3.27
19.1
14.1
25.20
24.29
mg/l
0.14
156
1405
69
466
1.72
3.20
2.7
2.6
396.83
371.69
umol/l
1.12
63
415
92
672
1.67
3.18
2.6
2.9
—
—
estimate
—
0
0
90
656
1.66
3.13
3.4
3.0
0.00
0.00
estimate
-0.00
24
146
77
541
1.68
3.07
3.9
4.7
6.10
9.45
mg/mmol
0.70
52
383
31
164
2.05
3.06
3.1
3.9
1.75
1.67
mmol/l
0.04
26
146
110
849
1.63
3.02
3.6
3.1
0.00
0.02
estimate
0.50
23
145
75
528
1.66
2.94
3.4
4.0
51.37
53.40
mg/l
0.04
50
376
109
844
1.62
2.92
3.7
3.1
0.00
0.00
estimate
-0.00
25
164
54
349
1.74
2.90
3.9
2.3
1.30
2.08
e6/l
1.42
54
311
85
621
1.63
2.87
5.4
3.8
9.65
9.11
mmol/l
0.41
77
553
65
447
1.66
2.77
3.8
2.8
0.35
0.43
e6/l
0.10
48
317
64
439
1.66
2.75
4.2
3.2
0.00
0.01
estimate
0.50
25
152
88
656
1.60
2.70
6.1
8.9
1.21
1.20
mmol/l
0.30
81
620
19
87
2.30
2.67
1.3
1.2
—
—
—
0
0
54
359
1.68
2.60
1.9
1.7
0.86
1.64
mg/l
1.52
44
270
182
1634
1.98
2.58
5.2
4.7
6.09
6.03
mmol/l
0.18
171
1534
66
466
1.61
2.50
3.8
3.3
2.35
2.34
mmol/l
0.27
59
427
30
169
1.91
2.49
3.2
4.2
7.39
7.38
ph
0.36
18
95
87
660
1.55
2.41
6.2
3.3
21.19
41.25
ng/l
1.69
63
431
10
35
2.95
2.24
1.2
1.2
3.71
3.82
mmol/l
—
10
35
37
231
1.73
2.22
2.9
3.2
151.13
119.66
ug/g
0.18
29
194
192
1776
2.19
2.19
6.2
4.9
1.21
1.28
mmol/l
2.48
186
1687
67
490
1.54
2.15
2.8
2.7
0.00
0.00
estimate
-0.00
22
132
161
1420
1.61
2.12
4.1
3.8
54.00
54.84
u/l
0.05
155
1359
15
69
2.27
2.10
1.3
1.5
—
—
—
0
0
69
520
1.49
1.90
1.9
2.0
—
—
—
0
0
186
1717
1.86
1.89
5.5
4.2
1.51
1.41
mmol/l
0.88
178
1628
95
763
1.45
1.89
12.0
11.0
0.00
0.00
e9/l
1.69
83
631
5
12
4.24
1.83
1.2
4.4
—
—
—
0
0
87
691
1.45
1.82
3.4
2.9
6.13
6.08
ph
0.19
59
416
8
29
2.83
1.81
1.1
1.5
—
—
—
0
0
16
81
2.06
1.80
1.9
5.1
94.96
95.08
ng/l
0.00
16
75
52
373
1.53
1.79
2.2
1.9
—
—
—
0
0
32
204
1.67
1.79
2.0
1.6
—
—
—
0
0
48
340
1.54
1.75
3.7
3.8
4155.16
462.32
ng/l
0.43
37
265
53
384
1.51
1.74
4.9
3.3
1.02
1.02
kg/l
0.39
35
245
21
119
1.85
1.74
1.0
1.2
—
—
—
0
0
21
121
1.82
1.66
2.1
1.9
0.00
0.00
estimate
—
5
32
91
739
1.41
1.65
1.7
2.1
1.62
1.50
mmol/l
0.56
77
633
8
33
2.48
1.55
1.1
1.8
—
—
—
0
0
37
254
1.56
1.55
3.0
2.7
0.25
0.52
e6/l
0.61
17
118
12
58
2.14
1.52
1.9
2.0
—
—
—
0
0
62
478
1.42
1.48
2.3
2.6
—
—
—
0
0
18
103
1.82
1.46
21.9
2.9
—
—
—
0
0
61
470
1.42
1.46
5.5
4.5
—
—
—
0
0
23
143
1.68
1.42
2.3
1.8
0.24
0.34
mg/l
0.48
15
70
28
188
1.57
1.30
1.6
1.5
—
—
—
0
0
8
36
2.27
1.25
2.3
3.1
—
—
—
0
0
23
149
1.61
1.23
1.1
1.0
—
—
—
0
0
25
167
1.57
1.19
3.9
8.2
10.00
7.99
mmol/l
0.88
25
161
34
246
1.46
1.13
1.2
1.2
9.97
24.92
iu/ml
—
9
61
30
214
1.47
1.07
2.7
1.7
—
—
—
0
0
23
155
1.54
1.06
6.4
2.1
—
—
—
0
0
23
155
1.54
1.06
6.3
2.1
—
—
—
0
0
23
155
1.54
1.06
6.4
2.1
—
—
—
0
0
23
155
1.54
1.06
6.3
2.1
—
—
—
0
0
18
116
1.60
1.00
2.8
3.3
—
—
—
0
0
0
29
0.00
0.98
0.0
22.6
—
1271.07
—
0
29
10
54
1.90
0.98
9.7
3.6
—
—
—
0
0
6
119
0.49
0.97
1.0
1.1
1.29
1.43
g/l
—
6
119
21
142
1.53
0.97
6.8
2.2
—
—
—
0
0
27
193
1.46
0.96
1.3
1.3
—
—
—
0
0
6
29
2.10
0.90
1.2
1.0
—
—
—
0
0
32
240
1.39
0.89
2.9
2.7
—
—
—
0
0
15
96
1.61
0.87
1.6
2.6
—
—
—
0
0
10
57
1.79
0.85
9.2
12.7
—
—
—
0
0
56
463
1.29
0.83
1.4
1.3
—
—
—
0
0
16
107
1.54
0.79
3.1
4.4
7.37
7.36
ph
0.18
11
87
32
247
1.35
0.76
7.9
11.1
104.91
104.30
mmol/l
0.44
32
247
65
554
1.25
0.75
6.1
7.3
—
—
—
0
0
5
24
2.11
0.75
1.8
3.6
6.96
7.27
pmol/l
—
5
24
7
38
1.87
0.74
1.1
2.8
8.00
8.23
kpa
—
7
38
19
135
1.45
0.72
2.0
1.9
—
—
—
0
0
29
223
1.35
0.71
1.3
1.4
235.00
309.77
titre
—
8
43
7
119
0.57
0.70
1.1
1.1
0.97
0.93
g/l
—
7
119
10
61
1.67
0.70
4.0
2.5
—
—
—
0
0
7
42
1.69
0.69
1.3
1.2
—
—
—
0
0
5
28
1.80
0.66
1.2
1.1
—
—
—
0
0
34
273
1.29
0.63
1.6
1.4
—
—
—
0
0
22
167
1.36
0.60
5.8
14.5
—
—
—
0
0
6
36
1.69
0.57
2.7
2.5
2.25
2.15
mmol/l
—
6
23
6
37
1.64
0.56
1.5
1.1
—
—
—
0
0
12
82
1.49
0.55
1.0
1.2
—
—
—
0
0
16
117
1.40
0.54
1.6
1.4
—
—
—
0
0
15
109
1.41
0.52
5.1
9.0
—
—
—
0
0
34
281
1.25
0.52
1.8
1.6
—
—
—
0
0
26
209
1.28
0.49
1.3
1.2
1.26
5.10
u/ml
1.07
18
85
33
277
1.23
0.45
1.4
1.8
—
—
—
0
0
5
32
1.58
0.42
1.0
1.3
—
—
—
0
0
22
179
1.26
0.39
1.4
1.2
—
—
—
0
0
12
91
1.34
0.34
1.4
1.2
—
—
—
0
0
6
45
1.34
0.34
2.0
1.8
—
—
—
0
0
23
197
1.19
0.27
1.4
1.7
—
—
—
0
0
22
189
1.18
0.25
7.9
16.3
95.68
95.86
%
0.10
22
182
0
11
0.00
0.21
0.0
1.4
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
5.4
—
2.70
—
0
11
0
11
0.00
0.21
0.0
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
2214.50
—
0
10
5
43
1.17
0.21
1.4
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
2.8
—
0.69
—
0
13
9
111
0.80
0.20
5.1
18.7
16.80
16.38
%
—
9
105
53
494
1.10
0.20
9.5
5.7
—
—
—
0
0
6
50
1.21
0.20
1.3
1.1
—
—
—
0
0
13
110
1.19
0.17
11.7
12.0
26.44
24.21
mmol/l
2.12
13
103
5
70
0.71
0.17
1.2
1.1
—
—
—
0
0
14
162
0.85
0.17
1.7
2.9
0.21
0.24
g/l
0.63
14
151
28
256
1.11
0.15
2.6
2.2
—
—
—
0
0
7
90
0.77
0.14
2.0
2.8
—
—
—
0
0
11
94
1.18
0.13
4.5
3.0
0.52
0.63
%
0.58
11
94
5
60
0.83
0.08
1.6
1.2
—
—
—
0
0
5
60
0.83
0.08
1.6
1.1
—
—
—
0
0
22
206
1.08
0.07
1.9
1.7
1081.37
1228.55
nmol/l
0.29
14
163
22
206
1.08
0.07
7.7
15.4
7.44
7.42
ph
0.68
13
105
19
184
1.04
0.00
8.2
16.7
130.95
125.71
g/l
0.42
19
178
24
242
0.99
0.00
1.3
1.5
—
—
—
0
0
0
8
0.00
0.00
0.0
2.6
—
—
—
0
0
0
8
0.00
0.00
0.0
1.5
—
8.97
—
0
8
0
8
0.00
0.00
0.0
1.1
—
0.00
—
0
8
0
5
0.00
-0.00
0.0
1.2
—
2.02
—
0
5
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
10.20
—
0
5
0
5
0.00
-0.00
0.0
3.0
—
53.80
—
0
5
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
4.6
—
27.20
—
0
5
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
112.40
—
0
5
0
9
0.00
-0.00
0.0
1.8
—
2.44
—
0
9
0
6
0.00
-0.00
0.0
2.2
—
7.27
—
0
6
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
9
0.00
-0.00
0.0
2.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.6
—
26.03
—
0
7
0
6
0.00
-0.00
0.0
2.7
—
333.50
—
0
6
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
4.0
—
14.40
—
0
5
0
7
0.00
-0.00
0.0
1.1
—
0.46
—
0
7
6
69
0.87
-0.00
1.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
14.87
—
0
6

Mortality – FinRegistry

↥

Association

Association between endpoint E4_TESTICDYSNAS and mortality.

Females

No data

Males

Parameter HR [95% CI] p-value
E4_TESTICDYSNAS 1.564 [1.05, 2.32] 0.026
Birth year 0.985 [0.98, 0.99] 0.002

During the follow-up period (1.1.1998 — 31.12.2019), 52 out of 694 males with E4_TESTICDYSNAS died.

Mortality risk

Mortality risk for people of age

years, who have E4_TESTICDYSNAS.

N-year risk Females Males
1 No data 0.294%
5 No data 1.847%
10 No data 4.324%
15 No data 8.11%
20 No data 13.644%

Relationships between endpoints

↥

Index endpoint: E4_TESTICDYSNAS – Testicular dysfunction, other/unspecified

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data